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ABSTRACT
Neuroblastoma is the most common pediatric cancer in infants, arising from the
sympathoadrenal lineage of the neural crest. Despite recent advances in other pediatric
cancers, long term survival in high risk cases of neuroblastoma remains below 40%.
Therefore, to develop successful therapeutics targeting high risk tumors, further research
into the mechanisms involved in high risk tumor formation is necessary. Prognosis in
neuroblastoma is determined by a number of factors, including certain genetic and
biological variables. The genetic variable correlated most with high risk disease is
amplification of the MYCN gene, which is present in ~25% of tumors. Additionally,
~70% of these MYCN-amplified tumors express the neurotrophin receptor TrkB, and its
ligand, brain-derived neurotrophic factor (BDNF), with concurrent expression of these
proteins correlated with high risk disease independent of MYCN-amplification status. To
better understand factors influencing MYCN-amplified tumor cell phenotype, and the role
of TrkB signaling in high risk neuroblastoma, the experiments in this dissertation
examined growth factor effects on MYCN-amplified tumor cells from the TH-MYCN
mouse model of neuroblastoma, as well as the creation, and expression of a constitutively
active TrkB receptor in a neural crest derived cell line.
Overexpression of MYCN targeted to the sympathoadrenal lineage by the
tyrosine hydroxylase (TH) promoter is sufficient to cause neuroblastoma in 100% of mice
homozygous for the transgene (TH-MYCN mice). Screening growth factors, in vitro
treatment of tumor cells from dissociated TH-MYCN tumors with ciliary neurotrophic
factor (CNTF) was found to promote differentiation marked by increased neurite
outgrowth, and withdrawal of actively dividing cells from the cell cycle. These effects
were both concentration dependent, and specific to CNTF, as all other neurotrophic
factors tested had no effect on differentiation. Furthermore, TH-MYCN tumor cells were
found to highly express the receptor for CNTF, CNTFR both in vitro and in vivo.
Testing the ability of CNTF to affect tumor growth in vivo, CNTF treatment attenuated
subcutaneous tumor growth of the TH-MYCN tumor-derived cell line NHO1S in wild
type 129/SvJ mice. Therefore, CNTF signaling may be a potential therapeutic target in
MYCN-amplified neuroblastoma.
In addition to being significantly correlated with a poor prognosis in
neuroblastoma, the presence of activated TrkB signaling promotes a more aggressive
phenotype in established neuroblastoma cell lines. However, whether TrkB signaling is
sufficient to transform neural crest derived cells had not been established. To determine
the role of TrkB signaling in malignant transformation, the two immunoglobulin-like (Ig)
ligand binding domains were removed from a full length rat TrkB receptor. Expression
of this receptor, termed IgTrkB, leads to elevated phosphorylated Erk levels in the
absence of ligand, indicating the receptor is constitutively active. When expressed in the
neural crest derived cell line NCM-1, constitutive TrkB signaling confers a highly
transformed phenotype characterized by enhanced proliferation, anchorage-independent
cell growth, anoikis resistance, and matrix invasion. Furthermore, IgTrkB NCM-1 cells
upregulate transcripts for a number of cancer promoting genes, in addition to the poor
prognosis marker MYCN. In vivo, IgTrkB NCM-1 cells form highly aggressive tumors,
requiring euthanasia of mice by 15 days following injection, while wild type cells fail to
grow. Thus, TrkB signaling is sufficient to transform cells derived from the neural crest.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

Introduction
Neuroblastoma is a pediatric cancer arising from the developing tissues of the
sympathoadrenal lineage of the neural crest. Although neuroblastoma is the most
common extracranial solid tumor in children, and the most common cancer in infants,
little is known about the etiology of the cancer, and disease free survival for stage 3 or 4
disease with current therapies remains extremely poor. Neuroblastoma is a uniquely
heterogeneous cancer in which, in rare cases patients can present with widespread
metastatic disease that will regress with support treatment alone, while those with high
risk disease often relapse following intensive chemotherapy. Thus, prognosis is
determined less by the size and spread of the tumor, as with most cancers, but more by
other factors such as, age of diagnosis, tumor histology, as well as the presence or
absence of genetic and biological variables in the tumor. To improve patient outcomes in
the high risk category we can not rely simply on earlier detection, rather, research efforts
need to focus on alternative strategies, such as identifying factors that can influence
tumor cell phenotype, and understanding the mechanisms involved in the pathogenesis
that occurs in the developing sympathetic nervous system that gives rise to high risk
disease. These efforts will allow the development of therapeutics that directly target
these derangements.
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High risk neuroblastoma tumors often lack differentiation, while more favorable
tumors are typically more differentiated, more closely resembling the neuronal lineage
from which they originated. Therefore, one strategy to treat high risk disease is to
identify factors which can promote differentiation of these poorly differentiated tumors,
making them less aggressive, and more amenable to surgical interventions or
chemotherapeutics. One of the goals of this dissertation was to identify such factors.

Additionally, although expression of the neurotrophin receptor TrkB and its
ligand brain-derived neurotrophic factor (BDNF) is correlated with a poor prognosis in
neuroblastoma, it is not known whether TrkB signaling itself is sufficient to give rise to
these aggressive tumors. TrkB regulated tumorigenesis would support this signaling
pathway as an important drug target in TrkB-expressing neuroblastoma. Therefore,
another goal of this dissertation was to determine if TrkB signaling would be sufficient to
transform neural crest cells.

Neuroblastoma

The Disease
Neuroblastoma represents approximately 8-10% of pediatric cancers but is responsible
for 15% of all pediatric cancer deaths (Gurney et al., 1997). Although improvements
have been made in patient outcomes, long-term survival in those with high risk disease
remains below 40% (Matthay et al., 1999; De Bernardi et al., 2003). Neuroblastoma
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tumors arise from the developing sympathoadrenal lineage. Although they can be found
anywhere in the sympathetic nervous system, approximately 50% develop in the adrenal
medulla, with the rest generally arising in paraspinal ganglia of the abdomen, chest, or
pelvis (Friedman and Castleberry, 2007). Presenting symptoms can vary greatly
depending on primary tumor site and the presence or absence of metastatic disease.
However, with most tumors arising in the abdomen (65%), symptoms are often vague,
including fatigue, loss of appetite, and a swollen abdomen. Clinical presentation for
neuroblastoma is separated into the three categories of localized, metastatic, and the
unique case of 4S disease.

Patients have localized disease in 40% of cases of neuroblastoma, with tumors
ranging from incidental findings on prenatal ultrasonography or chest radiographs, to
highly invasive local tumors (Maris et al., 2007). Paraspinal tumors arising along the
sympathetic chain can present as Horner’s syndrome when found in the cervical region
(Mahoney et al., 2006), or extend into spinal foramina, causing symptoms of spinal cord
and nerve root compression (De Bernardi et al., 2005). Overall, 5-15% of all
neuroblastoma patients will present with paraspinal tumors, and 5% of all patients will
present with signs of spinal cord compression, such as motor weakness or sensory loss
(De Bernardi et al., 2001). In addition to symptoms of mass effect from tumor growth,
patients with localized tumors can also present with paraneoplastic syndromes due to
tumor cell secretion of various factors, or autoimmune responses against tumor cell
antigens. These include tumor secretion of vasoactive intestinal peptide (VIP) leading to
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watery diarrhea and failure to thrive (Kaplan et al., 1980), as well as opsoclonusmyoclonus syndrome, which can lead to long-term neurological deficits in 70-80% of
patients (Mitchell et al., 2002).

Unfortunately, as high as 50% of neuroblastoma patients will present with
widespread metastatic disease, and unlike those with localized disease, are typically very
ill due to extensive tumor burden. Metastasies are often found in cortical bone, causing
bone pain, or the bone marrow, where marrow replacement can occur with symptoms of
marrow failure such as anemia (Quinn and Altman, 1979). Additionally, for unknown
reasons, neuroblastoma can often metastasize to the bony orbit, with patients in these
cases often presenting with periorbital ecchymoses (bilateral black eyes).

Interestingly, in about 5% of cases, patients will present with metastatic disease
that will spontaneously regress and be cured by supportive treatment alone. These
tumors, termed 4S (special), typically occur in younger patients and consist of small
primary tumors with metastasis to the liver, bone marrow, and skin (D'Angio et al.,
1971). Although typically these patients have a favorable prognosis, extensive hepatic
tumor growth can lead to hepatomegaly and respiratory failure in patients younger than 4
weeks of age (van Noesel et al., 1997).

Factors Affecting Prognosis
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Although, as in other neoplasms, the presence of localized versus metastatic disease at
the time of diagnosis is important in determining prognosis, in neuroblastoma prognosis
is largely dependent on additional factors including International Neuroblastoma Staging
System (INSS) stage, age at diagnosis, tumor pathology, MYCN amplification status, as
well as other genetic and biological variables such as Trk receptor expression. Because
of the extreme heterogeneity of disease these many different variables create,
neuroblastoma prognosis is currently separated into three risk categories: low,
intermediate, and high (Castleberry et al., 1997). In general, those with higher risk
disease have higher stage disease, are diagnosed later in life, and have tumors with
MYCN-amplification and unfavorable (less differentiated) tumor histology (Figure 1-1).
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Table 1-1: Neuroblastoma prognosis risk groups
*adapted from (Brodeur, 2003)
INSS
Stage
1
2A, 2B

Low Risk

Intermediate Risk

High Risk

None
None

None
Age 1-21 yrs and
MYCN AMP +
UH
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All
Age < 1 yr, or age 1-21
yrs and MYCN nonAMP, or age 1-21 yrs
and MYCN AMP + FH
None

Age < 1 yr and nonMYCN AMP, or age 121 yrs and MYCN nonAMP + FH

4

None

Age < 1 yr and MYCN
non-AMP

4S

MYCN non-AMP and
FH

MYCN non-AMP and
UH

Age 0-21 yrs and
MYCN AMP, or
age 1-21 yrs and
MYCN non-AMP
+ UH
Age < 1 yr and
MYCN AMP, or
age 1-21 yrs
MYCN AMP

AMP = amplified, UH = unfavorable histology (undifferentiated, higher mitosis-karyorrhexis index, MKI)
FH = favorable histology (differentiated, lower MKI)

Similar to many other malignancies, surgical staging, as defined by the
International Neuroblastoma Staging System (INSS) (Brodeur et al., 1993), is an
important prognostic indicator in neuroblastoma. Staging ranges from Stage 1 consisting
of fully resectable localized disease with negative ipsilateral lymph nodes, to stage 4
patients who present with widespread metastatic disease to the bone marrow or other
organs. Although those with the unique 4S subtype of neuroblastoma generally have a
good prognosis despite metastatic disease, typically, those with higher stage disease have
less favorable outcomes.
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In addition to surgical staging, patient age at diagnosis is important in determining
neuroblastoma prognosis. Those patients whom are diagnosed at 18 months of age or
less tend to have much better outcomes, with less aggressive forms of the disease
(London et al., 2005). Additionally, age might be an even better predictor of outcomes
than stage, as infants have much better outcomes than older patients with the same stage
disease. These outcomes are not simply dependent on delayed diagnoses, as studies on
mass-screening at the age of 6 months in Japan detected a 50-100% increase in the
prevalence of the neuroblastoma, but did not decrease the prevalence of the disease in
patients over one year of age (Sawada et al., 1984; Woods et al., 1996). Therefore, if
anything, mass screening leads to detection of tumors that would have spontaneously
regressed, subjecting children to unnecessary, and potentially harmful testing, surgery,
and chemotherapy. These outcomes suggest the existence of two subtypes of
neuroblastoma, a biologically favorable form of the disease arising in younger patients
(the screened population), and biologically unfavorable neuroblastoma forming in older
patients. Therefore, the context of sympathetic neural development in which
neuroblastoma tumorigenesis occurs may be important in determining tumor phenotype.

In addition to stage and age, by evaluating the pathological features of
neuroblastoma tumors, and relating those features to patient’s clinical outcomes,
favorable versus unfavorable histology has been developed as another prognostic tool
(Shimada et al., 1999). In general, those tumors that are more differentiated, and
therefore more closely resemble the tissue of the sympathetic nervous system from which

7

they have transformed, possess a more favorable prognosis. In addition to neuroblast
differentiation, other histological factors are taken into consideration when deeming a
tumor favorable versus unfavorable. These include the amount of Schwann cells present
in the stroma of the tumor (more being favorable), and the number of mitotic figures and
degenerating nuclei (mitosis-karyorrhexis index, MKI; lower MKI more favorable).
Additionally, tumors with a favorable prognosis typically express the neurotrophin
receptor TrkA, which may promote differentiation in the presence of nerve growth factor
(NGF), or tumor cell apoptosis in its absence.

Similar to the prognostic significance of age, the genetic features of
neuroblastoma tumors also suggest the presence of the two differently behaving subsets
of the disease. The first type consists of tumor cells with mitotic dysfunction, resulting in
hyperdiploid or near triploid karotypes with few cytogenic abnormalities such as
deletions, duplications, or amplifications. Children with these tumors tend to have more
favorable outcomes (Kaneko et al., 1987). On the other hand, poor prognosis tumors
typically have a near diploid karotype, but gross chromosomal abberations. Typically
these aberrations consist of either 11q and 14q deletions, or, in the most aggressive form
of neuroblastoma, 1p loss of heterozygosity (LOH) and the presence of MYCN
amplification as either double minutes (DM), or homogeneously staining regions (HSRs)
(Brodeur et al., 1997). In fact, the presence of MYCN amplification alone is one of the
strongest prognostic variables for a poor prognosis in neuroblastoma (Brodeur et al.,
1984). It is currently unknown what leads to amplification, however it is thought that

8

MYCN might be copied many times to form extrachromasomal circular DNA elements
(the DMs), which can then be integrated back into a particular locus in a chromosome to
form the HSRs. This genetic abnormality is found in approximately 22% of patients
(Brodeur et al., 1997), and is associated with a rapid tumor progression and a poor
prognosis even in infants, and in those with lower stages of disease (Seeger et al., 1985).
Furthermore, TrkB and BDNF are predominantly expressed in MYCN amplified tumors
(Nakagawara et al., 1994), where they may confer an autocrine survival pathway, while
TrkA is often expressed in non-MYCN amplified biologically favorable tumors,
promoting differentiation or apoptosis (Nakagawara and Brodeur, 1997). Therefore, one
of the focuses of neuroblastoma research needs to be identifying new strategies and
treatments for children with MYCN amplified tumors to improve these patient’s
outcomes.

All of these prognostic variables help categorize patients into the three risk groups
discussed above, which are based on the probability of death from the disease. These risk
groups then dictate the intensity of therapy a patient receives, from surgery alone in low
risk cases, to dose-intensive chemotherapy, surgery, radiation therapy, bone marrow
transplant, as well as adjuvant immunotherapy in patients diagnosed with high risk
neuroblastoma. Although, risk stratification is fairly clear for those with very low risk, or
very high risk disease with respect to age and stage, predicting outcomes in patients who
fall in between has been more difficult. Recently, a new International Neuroblastoma
Risk Group (INRG) classification system, separating risk groups into very low, low,
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intermediate, and high risk, has been proposed to try to better stratify patients to the
proper treatment strategies (Cohn et al., 2009). Despite advances in risk stratification,
these risk groups are simply surrogates for different underlying biological subtypes of
neuroblastoma. Therefore, understanding the pathogenesis that gives rise to biologically
unfavorable neuroblastoma, and developing new therapeutic strategies to treat the
disease, are crucial to improving outcomes in this patient population.

Genetic Factors Contributing to Disease
Unlike some cancers, where a single genetic mutation is characteristic of the disease,
genetic factors leading to neuroblastoma are much more complicated and not well
known. Although most cases of neuroblastoma are sporadic, 1-2% of cases do show a
family history with autosomal dominant inheritance (Shojaei-Brosseau et al., 2004).
Recently, it was discovered that activating mutations in the anaplastic lymphoma kinase
(ALK) gene are responsible for the majority of cases of familial neuroblastoma (George et
al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008), as well as mutated in 5-15%
of sporadic cases (Chen et al., 2008; George et al., 2008). The exact function of the wild
type ALK protein is yet to be fully determined, but it is expressed in the developing
nervous system (Iwahara et al., 1997; Trochet et al., 2004), and can influence
proliferation of developing sympathetic precursors (Reiff et al., 2011). Disruptions of
another gene, PHOX2B, less common than mutations in ALK, have also been linked to
familial neuroblastoma. These missense or frame shift mutations result in loss-offunction of the Phox2b protein (Mosse et al., 2004; Trochet et al., 2004). Similar loss-of-
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function mutations have been identified in a small number (2.3%) of sporadic tumors as
well (van Limpt et al., 2004).

Although mutations of the cell cycle genes CDK6 (Easton et al., 1998) and
CYCLIND1 (Easton et al., 1998; Molenaar et al., 2003) in single cases have been
reported, other than ALK and PHOX2B, additional inheritable genetic causes of
neuroblastoma have been limited to the identification of polymorphisms predisposing to
an increased risk of disease. Genome-wide association studies (GWAS) have begun to
uncover these genetic variations that, along with enumerable other variables, such as
environmental influences, lead to sporadic neuroblastoma tumorigenesis. Single
nucleotide polymorphisms (SNPs) at the putative genes FLJ22536 (Maris et al., 2008)
and BARD1 (Capasso et al., 2009), and the gene LMO1 (Wang et al., 2011) have been
identified to be significantly enriched among neuroblastoma patients. Additionally, in
the cases of BARD1 and LMO1, these polymorphism code for proteins leading to
enhanced oncogenic potential (Bosse et al., 2011), confirming their likely role in
neuroblastoma formation.

Neuroblastoma – a Neural Crest Derived Tumor

Neural Crest Development
Neuroblastoma is a malignancy arising from the developing sympathoadrenal (SA)
lineage of neural crest. The neural crest is a transitory structure that arises from the
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neural tube early in development following neural tube closure. Soon after specification
from the neural tube, trunk neural crest cells undergo an epidermal to mesenchymal
transition (EMT), becoming a migratory, multipotent population of precursor cells that
have the ability to differentiate into a number of cell types including glia, melanocytes,
sensory neurons, and SA precursors (Baroffio et al., 1988; Dupin et al., 1990). Since
neuroblastoma can form in the adrenal medulla, in addition to anywhere in the
sympathetic nervous system, it is thought to arise from this SA precursor population,
which has the ability to give rise to sympathetic neurons, and the chromaffin cells of the
adrenal medulla (Anderson et al., 1991).

Specification of neural crest cells to the SA lineage involves the exposure of
developing neural crest cells to specific growth factors, as well as the expression of
particular transcription factors (Figure 1-1). The main family of growth factors
specifying commitment to the SA lineage is the bone morphogenic protein (BMP) family.
As shown by inhibition studies, BMPs, which are expressed in the dorsal aorta where
sympathoadrenal progenitors coalesce following their migration from above the neural
tube (Shah et al., 1996), are essential for initiation of differentiation to the sympathetic
lineage (Schneider et al., 1999). The first pro-neural gene expressed in this progenitor
population is ASCL1, encoding the basic helix loop helix (bHLH) transcription factor
hASH1 (or mASH1 and cASH1 in the mouse and chicken, respectively). Rather than
induce expression of ASCL1, which is in fact expressed in SA progenitor cells around the
dorsal aorta prior to BMP expression, BMPs are thought to maintain expression of
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ASCL1 in SA precursors (Lo et al., 1997). Following expression ASCL1, further
specification of SA progenitors involves the coordinated gene expression of ASCL1,
PHOX2A, PHOX2B, and HAND2 (Hirsch et al., 1998; Stanke et al., 1999; Howard et al.,
2000).

PHOX2B codes for a homeodomain DNA binding protein that plays an important
role in the development of the SA lineage. Although hASH1 induces expression of
PHOX2B, Phox2b can reciprocally induce expression of ASCL1. Furthermore, Phox2b,
but not hASH1, is able to induce expression PHOX2A and HAND2. In turn, Hand2,
another bHLH transcription factor, then reciprocally upregulates expression of ASCL1
and PHOX2B, forming an autocrine loop of transcription factor expression promoting
neural crest progenitor cells to the SA lineage (Bertrand et al., 2002). Following
commitment to the SA lineage by this coordinated transcription factor expression, SA
progenitor cells begin to express neuronal and catecholaminergic specific genes such as
tyrosine hydroxylase (TH), dopamine beta-hydroxylase (DBH), neurofilament (NF), and
SCG10, and then migrate from the dorsal aorta to form the secondary sympathetic
ganglia and adrenal medulla, where further specification to sympathetic neurons and
chromaffin cells occurs (Huber, 2006). Further specification of SA progenitors to a
sympathetic neuronal fate involves expression of a number of proteins including the
neuroblastoma poor prognosis marker MYCN, another DNA binding transcription factor.
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Late stage and terminal differentiation to mature sympathetic neurons requires
subsequent neurotrophin signaling. Following commitment to sympathetic neurons, SA
begin to express TrkC and become dependent on the TrkC ligand neurotrophin-3 (NT-3)
for survival (Birren et al., 1993). In addition to TrkC, sympathoblasts simultaneously
transiently express TrkB (Straub et al., 2007). However, TrkB’s role in sympathetic
development remains unclear, as there is no apparent sympathetic phenotype in TrkB or
BDNF-knockout mice (Schober et al., 1997). Following TrkC expression,
sympathoblasts begin to express TrkA and their trophic dependence shifts as they
differentiate to mature sympathetic neurons, with nerve growth factor (NGF) becoming
the predominant factor supporting their survival (Birren et al., 1993).
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Figure 1-1: Sympathetic specification from the neural crest
*adapted from (Mohlin et al., 2011)

Neuroblastoma and the Neural Crest Lineage
In addition to the simple fact that neuroblastoma can arise anywhere in the distribution of
the sympathoadrenal lineage, additional lines of evidence from the differentiation of the
SA from the neural crest confirm neuroblastoma as a malignancy of the developing
sympathetic nervous system. ASCL1, the first transcription factor expressed in neural
crest cells destined for the SA lineage, is expressed at high levels in many
neuroblastomas (Soderholm et al., 1999; Ichimiya et al., 2001). This expression suggests
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that in some cases transformation may occur at this early stage of SA development, or
alternatively these tumor cells may be reverting back to a less differentiated state.
Despite this persistence of ASCL1 expression, these cells are able to respond to
differentiation cues, as differentiation of hASH1 positive neuroblastoma cells by retinoic
acid treatment leads to down regulation of ASCL1 expression (Soderholm et al., 1999;
Ichimiya et al., 2001).

Phox2b is also important in both SA development and neuroblastoma. As
mentioned above, mutation of the PHOX2B locus is one of the few known causes of
familial neuroblastoma (Mosse et al., 2004; Trochet et al., 2004; Bourdeaut et al., 2005).
Interestingly, although mutation in these familial cases leads to loss of function of the
gene, suggesting PHOX2B to be a tumor suppressor, tumor samples and cell lines
harboring similar PHOX2B mutations express the downstream target gene DBH,
suggesting these mutations are not dominant negative (van Limpt et al., 2004; Longo et
al., 2008). In any case, disruption of PHOX2B is clearly sufficient to drive
neuroblastoma formation, although the mechanism involved is yet to be determined.
Hand2, whose expression is initiated by Phox2b during SA progenitor development, is
also frequently expressed in neuroblastoma. However, its expression does not correlate
with clinical stage (Gestblom et al., 1999), indicating Hand2, unlike Phox2b, is unlikely
to be a driver of tumorigenesis in neuroblastoma.
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Expression of MYCN in neuroblastoma, most often in the form of amplification of
the gene, is well established as a marker of biologically unfavorable tumors. Like MYC,
the MYCN protein is known to bind MAX, with this heterodimer activating transcription
of genes that lead to progression through the G1 phase of the cell cycle, which in the
brain is important in expansion of the neuronal progenitor cell population (Knoepfler et
al., 2002). However, in addition to regulating proliferation, studies in mycn knockout
mice suggest the transcription factor is important differentiation as well (Sawai et al.,
1993). Although, at this point it is not clear whether MYCN is predominantly involved
in proliferation or differentiation during SA development from the neural crest,
transformation occurring at the MYCN-expressing stage seems to lead to an aggressive
MYCN amplified form of neuroblastoma. Furthermore, the importance of MYCN in
neuroblastoma tumorigenesis is highlighted by the fact that MYCN overexpression alone
is sufficient to initiate tumor formation, as transgenic mice that express MYCN under the
tyrosine hydroxylase promoter (TH-MYCN mice) form tumors in 100% of mice
homozygous for the transgene (Weiss et al., 1997). Although penetrance of tumor
formation is highly strain specific, suggesting other factors are likely involved in MYCNmediated transformation, TH-MYCN mice provide a model to study primary MYCN
amplified neuroblastoma tumor cells in culture, as well as in vivo. Experiments
described in this dissertation employ the use of this model in an effort to discover growth
factors that can promote a more differentiated phenotype in MYCN amplified tumor cells.

Trk Signaling
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The Role of Trks in Sympathetic Development
As mentioned above, neurotrophin signaling through Trk receptors is important in late
stage sympathetic neuron development; and the role of Trks in neuroblastoma affords a
more in-depth discussion of neurotrophin signaling in sympathetic development.
Interestingly, prior to being found to be the high affinity receptor for NGF, the Trk gene
was first discovered as an oncogene fused to the tropomyosin gene promoting continuous
proliferation in colon cancer cells. There are now known to be three members of the
tropomyosin receptor kinase (Trk) family, TrkA, TrkB, and TrkC to which neurotrophins
differentially bind (Snider, 1994). TrkA preferentially binds NGF, TrkB binds BDNF
and neurotrophin-4/5 (NT-4/5), and TrkC binds neurotrophin-3 (NT-3). In addition to the
Trk family of neurotrophin receptors, all members of the neurotrophin family also bind
the p75, or low affinity nerve growth factor receptor (LNGFR), a member of the tumor
necrosis factor receptor (TNFR) family (Snider, 1994). During development, each
receptor / ligand combination has specific functions. Signaling through the NGF / TrkA
ligand-receptor complex supports survival and differentiation of sympathetic neurons and
sensory neurons that respond to pain and temperature (Smeyne et al., 1994). BDNF /
TrkB and NT-4/5 / TrkB signaling supports sensory neurons responsible for relaying
tactile stimuli and motor neurons respectively, while NT-3 / TrkC signaling supports
early sympathetic progenitors (Birren et al., 1993) and sensory neurons responsive to
limb movement and position (Klein et al., 1993; Klein et al., 1994).
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TrkA expression is abundant throughout the sympathetic nervous system. As
mentioned above, TrkA supports survival and differentiation of developing SA
progenitors into terminally differentiated sympathetic neurons. During development,
TrkA expression is detected in most cells by embryonic day (E) 16, and intense labeling
occurs by E18 in the rat (Ernfors et al., 1992). In mice, TrkA mRNA expression is
detected by in situ hybridization starting at E13.5 and increasing through E15.5 until birth
(Fagan et al., 1996). Expression is similar in the chick, with TrkA initially seen at E5
followed by all neurons appearing immunoreactive by E8 (Straub et al., 2007).
Furthermore, TrkA expression is not restricted to the developmental period, as TrkA is
highly expressed in the adult sympathetic nervous system of rats (prevertebral,
paravertebral, and superior cervical ganglia [SCG]), as well as humans (paravertebral
ganglion) (Wetmore and Olson, 1995; Garcia-Suarez et al., 1996; Schmidt et al., 1998).

Functionally, TrkA signaling is very important in early sympathetic neuron
survival and development. This has been established by a number of studies involving
NGF treatment, and TrkA mutant mice. Injection of NGF in postnatal mice causes a twoto three-fold increase in the size and cell number of SCG and thoracic sympathetic
ganglia (Levi-Montalcini and Booker, 1960b; Black et al., 1972). On the other hand,
treatment with anti-NGF antiserum leads to massive neuronal loss in the postnatal mouse
SCG (Levi-Montalcini and Booker, 1960a). These effects are not limited to the postnatal
period, as transuterine NGF injection leads to an increase in sympathetic neurons, and
treatment of pregnant mice with antiserum leads to an 80% loss of neurons in the SCG
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and stellate ganglion of offspring (Kessler and Black, 1980). In TrkA mutant mice,
innervation of the submaxillary gland by tyrosine hydroxylase (TH) positive sympathetic
fibers is disrupted throughout development (Fagan et al., 1996). Therefore, TrkA
signaling is critical for the survival of developing sympathetic precursors, and the proper
development of the sympathetic nervous system.

As mentioned above, like TrkA, TrkC is expressed in the sympathetic nervous
system, however the majority of this expression is limited to early developmental period
when TrkC signaling can support early sympathoblast survival. In the rat, TrkC is first
expressed at E13, before the onset of TrkA expression at E16 (Ernfors et al., 1992). After
E17.5 TrkC expression decreases rapidly to the point that it is reduced by an order of
magnitude by birth (DiCicco-Bloom et al., 1993). A similar pattern of expression occurs
in both the mouse, with the onset of expression at E11.5 increasing to E13.5 and then
restricted to only a few cells by birth (Fagan et al., 1996), and the chick, with expression
seen at E6.5 downregulated by E8 (Straub et al., 2007). In humans, TrkC is expressed in
only 10% of cells in adult sympathetic ganglia (Garcia-Suarez et al., 1996). However,
despite this consistent expression pattern across species, and the ability of TrkC to
support the survival of early sympathoblasts (Birren et al., 1993), TrkC expression does
not appear necessary for normal sympathetic development, as TrkC knockout mice show
no loss of SCG neurons (Tessarollo et al., 1997). This might be explained by the ability
of NT-3 to activate TrkA in the absence of TrkC expression. Indeed, unlike TrkC
mutants, NT-3 mutant mice have a 35-50% reduction in the number of SCG neurons
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(Francis et al., 1999). Thus, although TrkC is consistently expressed in during
sympathetic development, its expression is not required.

Compared to TrkC, the expression of TrkB in the sympathetic nervous system is
even more limited. In the mouse, TrkB expression has been observed in embryonic
sympathetic ganglia by in situ hybridization (Schecterson and Bothwell, 1992), and
immunohistochemically at E13 and E15, co-expressed with tyrosine hydroxylase (Straub
et al., 2007). Although, in the SCG of 3 day to 4 week old rats, TrkB mRNA is barely
detectable, it is seen in low but significantly higher levels in the prevertebral ganglia
(Dixon and McKinnon, 1994). In the chick, TrkB immunoreactivity has been observed
transiently in embryonic sympathetic ganglia starting at E5 and was lost by E8 (Straub et
al., 2007). Interestingly, these TrkB-expressing sympathoblasts proliferate in response to
BDNF in culture. In the adult, unlike TrkA and TrkC, TrkB immunoreactivity has not
been detected in human sympathetic ganglia, and very few neurons express TrkB mRNA
in adult rat SCG (Wetmore and Olson, 1995; Garcia-Suarez et al., 1996). Thus, TrkB
appears to be expressed in a limited capacity in the developing mammalian and avian
sympathetic nervous system.

Current evidence suggests TrkB / BDNF signaling has a limited functional role in
sympathetic nervous system development. In either BDNF or TrkB mutant mice, there is
no significant change in SCG size or neuron number (Ernfors et al., 1994; Fagan et al.,
1996). Although, transgenic mice overexpressing BDNF under the α-mysosin heavy
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chain promoter show a hyperinnervation of TH-positive neurons in the arrector pili
muscle in the skin (Botchkarev et al., 1998), whether this effect is mediated through the
few existing TrkB expressing sympathetic neurons or the low affinity neurotrophin
receptor p75 has not been established.

The Significance of Trk Receptor Expression in Neuroblastoma
From the above discussion it is clear that TrkA is highly expressed and instrumental in
sympathetic nervous system development, TrkC is consistently expressed and appears to
play an early role, while TrkB expression is limited with no apparent function in normal
sympathetic development. These expression patterns and functions in sympathetic
nervous system development may partly explain the differences in tumor phenotype
observed in neuroblastoma tumors expressing Trk receptors and their ligands.
Expression of TrkA or TrkC and their respective ligands are important in sympathetic
development and differentiation, and there expression in neuroblastoma leads to a less
aggressive and more differentiated phenotype. On the other hand, expression of TrkB,
which has no role in sympathetic differentiation, but can promote proliferation (Straub et
al., 2007), is correlated with an aggressive and highly proliferative tumor cell phenotype,
possibly representing cells stuck in a transient sympathoadrenal precursor stage, lacking
the proper Trk receptor signaling to properly differentiate.

TrkA is expressed in biologically favorable tumors. High expression of the
receptor is associated with favorable clinical features, inversely correlated MYCN
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amplification (Nakagawara et al., 1992), and strongly predictive of a favorable outcome
(Nakagawara et al., 1993). TrkA expression is a marker of biologically favorable tumors,
and likely also contributes to this phenotype, as TrkA expressing tumor cells are able to
respond to NGF treatment with enhanced survival and terminal differentiation like
normal sympathetic neurons (Nakagawara and Brodeur, 1997). Furthermore, consistent
with the hypothesis of trophic dependence in sympathetic neurons, when these same
TrkA expressing cells are cultured in the absence of NGF they undergo apoptosis within
7 days. The ability of TrkA expressing neuroblastoma to appropriately respond to the
presence or absence of NGF by differentiating or undergoing apoptosis may explain the
ability of some favorable neuroblastomas, especially 4S tumors, to spontaneously
undergo differentiation and regression. Recently, a developmentally regulated TrkA
splice variant (TrkAIII) that splices out exons 6, 7, and 9 has been identified (Tacconelli
et al., 2004). Interestingly, this splice variant, expressed exclusively in undifferentiated
neuronal precursors, is constitutively active. Although, TrkAIII appears to be expressed
more often in higher stage neuroblastomas, its presence is consistent with the typically
undifferentiated phenotype of these tumors.

Like TrkA, expression of TrkC is found in biologically favorable neuroblastomas.
The receptor is expressed in about 25% of primary neuroblastomas, and these tumors
essentially represent a subset of TrkA-expressing tumors (Yamashiro et al., 1996).
Furthermore, TrkC-expressing tumors are correlated with younger age, lower stage, and a
lack of MYCN amplification (Ryden et al., 1996). NT-3 does not appear to be
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appreciably expressed in primary neuroblastomas (Yamashiro et al., 1997). Therefore,
TrkC, like TrkA in the absence of NGF, may promote apoptosis and regression in the
more favorable tumors that express the receptor.

Unlike TrkA and TrkC, expression of TrkB and its ligand, BDNF, is a strong
predictor of an aggressive tumor phenotype and poor prognosis in neuroblastoma.
Understanding how TrkB, a receptor normally only transiently expressed in the
developing sympathetic nervous system, contributes to neuroblastoma tumorigenesis is
crucial to developing successful targeted therapies for poor-prognosis neuroblastoma.
TrkB and BDNF are predominantly expressed in aggressive, treatment resistant
neuroblastoma, where this signaling pathway can act in an autocrine manner to promote
metastasis (Matsumoto et al., 1995; Brodeur et al., 2009). Tyrosine kinase activated
signaling pathways are required for TrkB-mediated aggressiveness in neuroblastoma
tumors, as a truncated TrkB isoform which lacks the tyrosine kinase signaling domain, is
found in more differentiated tumors such as ganglioneuroblastomas (Nakagawara et al.,
1994). In these tumors, truncated TrkB can act as a dominant negative inhibitor of full
length TrkB signaling (Haapasalo et al., 2001)

TrkB signaling promotes an aggressive tumor cell phenotype in neuroblastoma by
mediating cell growth, survival, adhesion, and metastasis through pathways activated
normally by Trk signaling; these are the RAS, PI3K, and Rho signaling pathways. The
primary signaling pathway involved in promoting cell growth is the Ras-MAPK/Erk
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signaling cascade. Upon receptor activation, phosphorylation of the tyrosine residue
Y490 is followed by phosphorylation of Shc, and recruitment of the adapter protein Grb2
complexed to the RAS exchange factor SOS. This complex stimulates RAS by
promoting activation of the RAS-Raf-MEK-MAPK-Erk pathway, resulting in cell growth
and proliferation (Kao et al., 2001). TrkB-mediated cell survival is primarily regulated
by activation of the PI3K pathway (Yao and Cooper, 1995), which can be both RASdependent, and -independent. Independent of upstream RAS activation, PI3K can be
activated through Shc, Grb2, or Irs1 (Reichardt, 2006). PI3K activation leads to the
activation of the serine threonine kinase Akt that modulates a number of factors
important in cell death pathways including Bad, Caspase-9, GSK3, and IB. TrkB
activation can also modify adhesion molecules, such as cadherin (Zhou et al., 1997),
membrane chondroitin sulfate proteoglycan (MCSP) (Schulte et al., 2005), and signaling
pathways, such as the Cdc42-Rho-Rac-actin pathway (Miyamoto et al., 2006) that are
important in the regulation of adhesion and metastasis.

A number of ex vivo studies have further elucidated how TrkB signaling promotes
a biologically unfavorable phenotype in neuroblastoma. In the TrkB-expressing
neuroblastoma cell line, SMS-KCN, treatment with BDNF enhances cell survival in
serum-free media (Nakagawara et al., 1994; Feng et al., 2001). Furthermore, BDNF
treatment of TrkB-expressing neuroblastoma cells enhances their invasiveness
(Matsumoto et al., 1995; Cimmino et al., 2009), and renders them less sensitive to
cytotoxic drugs (Scala et al., 1996; Ho et al., 2002; Jaboin et al., 2002; Li et al., 2005; Li

25

et al., 2007; Baj and Tongiorgi, 2009). In addition, TrkB activation by BDNF in SY5Y
neuroblastoma cells increases production of the pro-angiogenic molecule VEGF
(Nakamura et al., 2006), while expression of TrkA down-regulates expression and
function of angiogenic stimulator in this same cell line (Eggert et al., 2002). Therefore,
concomitant expression of both full length TrkB and BDNF likely forms an autocrine or
paracrine survival pathway in the associated aggressive poor prognosis tumors.

Furthermore, an active TrkB signaling pathway may be important in the
propensity of a high risk patient population to succumb to relapse following
chemotherapy. It has been shown that neuroblastoma cells that survive repeated
exposures to cytotoxic drugs express increasing levels of BDNF; this may help confer
survival and multidrug resistance in these cells (Matsumoto et al., 1995). The increases
in BDNF levels, coupled with hypoxia, cause increases in TrkB expression (Martens et
al., 2007), and may provide a situation in which the microenvironment within the tumor
is able to respond to environmental insults (such as chemotherapeutics) to promote
survival of tumor cells, and eventual relapse. These survival effects are mediated in part
by activation of PI-3kinase (Jaboin et al., 2002) and Akt (Li et al., 2005), and inactivation
of GSK3 (Li et al., 2007), as in normal Trk expressing cells. Additionally, even in
tumor cells in which TrkB expression is low, local environments rich in BDNF may be
able to support the survival of these cells and protect them from chemotherapeutics,
setting the stage for later relapse. For instance, in multiple myeloma, bone marrow-
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derived BDNF is able to activate TrkB-expressing multiple myeloma cells and promote
drug resistance via the PI-3kinase / Akt pathway (Pearse et al., 2005).

As well as increasing survival in neuroblastoma cells, activation of the TrkB
signaling pathway also promotes migration, invasiveness, and metastatic potential. In
SY5Y and SK-N-AS neuroblastoma cells, TrkB signaling enhances tumor cell
invasiveness in an autocrine manner, increasing the expression of hepatocyte growth
factor (HGF) and its receptor, c-MET (Hecht et al., 2005). Furthermore, in vitro, SY5Y
cells transfected with TrkB, but not those transfected with TrkA, display increased
invasiveness mediated by upregulation of galectin-1 (Gal-1) (Cimmino et al., 2009).
Thus, research with neuroblastoma cell lines demonstrates the ability of TrkB signaling
to promote a more aggressive tumor cell phenotype, suggesting the expression of TrkB /
BDNF is causal in the aggressive and biologically unfavorable nature of tumors that
express the receptor and ligand.

Despite evidence demonstrating the role of TrkB signaling in neuroblastoma cell
lines, there has been little in vivo work showing how aberrant TrkB signaling might
contribute to tumorigenesis, or whether TrkB signaling is sufficient to transform normal
neural crest precurors. Developing sympathoadrenal precursors transiently express TrkB
in vivo, and are able to proliferate in response to BDNF ex vivo (Straub et al., 2007),
suggesting that aberrant TrkB signaling in vivo may be sufficient to cause transformation
in neuroblastoma. By examining the effects of expression of a constitutively active TrkB
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receptor in a neural crest derived cell line, experiments presented in this dissertation
suggest TrkB signaling can be an initiator of tumor formation in neuroblastoma.

Summary
Taking into account the development of the sympathoadrenal lineage from the neural
crest, the heterogeneity of disease seen in neuroblastoma tumor phenotypes is likely a
result of tumors arising from different points in the developmental program. It seems
likely that biologically unfavorable tumors arise from an earlier point in development,
and like early precursors, are undifferentiated, highly proliferative, and express TrkB. On
the other hand, biologically favorable tumors appear to arise later in development, and
more closely resemble normal sympathetic neurons by virtue of expressing TrkA and
TrkC, and responding appropriately to differentiation / apoptotic cues transmitted by
these receptors. Ultimately, the development of new strategies that can shift poor
prognosis tumors to the more differentiated state of biologically favorable tumors may be
of therapeutic benefit. Furthermore, determining what aspects of biologically
unfavorable tumors – such as MYCN amplification or TrkB signaling – are sufficient to
drive neuroblastoma formation, will be important in targeting specific therapeutics for
these derangements.
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Abstract
Neuroblastoma is a pediatric malignancy arising in tissues of the sympathoadrenal
lineage. Elevated expression of the transcription factor MYCN in tumor tissue is
associated with poor clinical outcomes, and MYCN overexpression targeted to the neural
crest lineage by the tyrosine hydroxylase (TH) promoter is sufficient to cause
neuroblastoma in transgenic mice (TH-MYCN). Ciliary neurotrophic factor (CNTF) is a
neuropoietic cytokine known to influence survival, differentiation, and proliferation in
developing sympathetic neurons; therefore we determined whether TH-MYCN tumors
respond to CNTF by differentiating. We found that TH-MYCN tumors predominantly
arise in the celiac ganglia and many cells express CNTFR alpha. In cell culture, CNTF
increases process outgrowth and decreases proliferation of cells derived from TH-MYCN
tumors with an EC50 of approximately 0.4 ng/mL. CNTF promotes differentiation by
first inducing cell cycle withdrawal rather than by causing a non-mitotic population to
extend neurites. In vivo, CNTF treatment attenuated subcutaneous tumor growth of the
TH-MYCN tumor-derived cell line NHO1S in wild type 129/SvJ mice. Thus, activation
of the CNTF receptor overrides the proliferative effect of N-MYC, suggesting a possible
therapeutic target for poor prognosis, MYCN amplified tumors.

Introduction
Neuroblastoma is the most common extracranial solid tumor in children, and outcomes
remain poor for many patients who present with the cancer at 18 months or older.
Prognosis is stratified into low, intermediate, and high risk categories (Maris et al., 2007)
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based on the biological heterogeneity of the disease, with the most consistent genetic
aberration correlating with high risk disease being amplification of the MYCN gene,
which occurs in approximately one third of primary tumors (Maris and Matthay, 1999).
These poor prognosis MYCN amplified tumors are typically stroma-poor and lack
differentiation, while non-amplified tumors, tend to be stroma-rich, less aggressive, and
more differentiated, suggesting factors in the tumor microenvironment may be important
in determining tumor phenotype (Shimada et al., 1984). Furthermore, MYCN expression
can disrupt responses to normal developmental cues, as sympathetic neurons
overexpressing the MYCN protein reenter S phase and resist cell death induced by nerve
growth factor (NGF) withdrawal (Wartiovaara et al., 2002). Therefore, agents promoting
differentiation of MYCN amplified tumors may improve outcomes in high risk
neuroblastoma.

Previously, a mouse model of neuroblastoma was generated by targeting
expression of MYCN to the neural crest lineage using the rat tyrosine hydroxylase (TH)
promoter (Weiss et al., 1997). 100% of mice homozygous for the TH-MYCN transgene
develop tumors, however tumor penetrance is strain specific, as mice on the C57B6/J
background develop tumors by 16 weeks of age (Hansford et al., 2004), as opposed to
only 6.5 weeks in 129/SvJ mice carrying the transgene. These tumors show typical
histopathological features of human neuroblastoma (Moore et al., 2008), as well as
genetic aberrations similar to those found in the human disease (Weiss et al., 2000;
Hackett et al., 2003). Therefore, TH-MYCN mice represent a mouse model for studying
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MYCN expressing primary tumor development, as well as the properties of MYCN
expressing primary tumor cells in culture.

In addition to the presence or absence of MYCN amplification, the degree of
tumor differentiation, which in both normal neuronal development and neuroblastoma is
influenced by growth factor signaling, is another important factor in determining patient
prognosis. Children diagnosed with tumors with increased differentiation have a better
probability for disease-free survival (Shimada et al., 1984). Differentiation is influenced
predominantly by the NGF/TrkA and BDNF/TrkB growth factor signaling pathways,
with TrkA expressed primarily in more differentiated biologically favorable tumors and
an active TrkB pathway often found in poor prognosis MYCN-amplified cases
(Nakagawara et al., 1993; Nakagawara et al., 1994). Furthermore, transfection of SY5Y
neuroblastoma cells with the TrkA receptor confers on these cells the ability to
differentiate in response to NGF (Lavenius et al., 1995), while conversely, transfection
with the TrkB receptor renders these cells resistant to chemotherapeutics (Ho et al.,
2002). In addition to TrkA and TrkB, other growth factor pathways have been shown to
be important in determining neuroblastoma tumor cell phenotype. Activation of the
epidermal growth factor receptor (EGFR) promotes proliferation in SY5Y and NLM cells
(Ho et al., 2005), and SMS-KCNR cells differentiated by retinoic acid express
transforming growth factor beta 1 (TGF-beta 1) and its receptors (Cohen et al., 1995).
Little is known about the effects of other factors known to be trophic in sympathetic
neurons.
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Here we report that the neuropoietic cytokine, ciliary neurotrophic factor (CNTF),
promotes differentiation and cell cycle withdrawal in tumor cells isolated from THMYCN mice. Furthermore, CNTF treatment attenuates growth of the TH-MYCN tumorderived cell line NHO1S in vivo. These results suggest the CNTF signaling pathway may
represent an important target for differentiating poor prognosis MYCN-expressing tumors.

Materials and methods
Ethics Statement: This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional Animal
Care and Use Committee of the University of Vermont (Animal Welfare Assurance
Number, A3301-01; IACUC protocol number 07-114). Every effort was made to
minimize suffering of the animals used.

Mice: TH-MYCN mice homozygous for the human MYCN cDNA under the rat tyrosine
hydroxylase promoter (Weiss et al., 1997) on a 129/SvJ genetic background were used
for all experiments involving TH-MYCN tumor removal and growth in culture. WT
129/SvJ mice were used for in vivo experiments with NHO1S cells, a cell line derived
from TH-MYCN mouse tumors.
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Immunostaining: Tumors were removed and immersion fixed overnight in Zamboni's
fixative (4% (w/v) paraformaldehyde, 15% (v/v) picric acid in 0.1 M sodium phosphate
buffer, pH 7.4). Tumors were washed with PBS to remove fix and equilibrated in 15%,
and then 30% sucrose overnight at 4C. Tissue sections of 20 mm thickness were cut
using a Microm HM 560 cryostat (Thermo Scientific) and mounted on SuperFrost Plus
slides (Fisher Scientific). Sections were post-fixed 15 minutes in Zamboni’s fixative and
placed into blocking solution (1x PBS consisting of 10% (v/v) heat-inactivated horse
serum (Invitrogen), 0.5% Triton X-100 (Sigma), and 0.1% sodium azide (Fisher
Scientific)) overnight at 4C. Sections were stained with primary antibodies overnight at
4C, followed by secondary antibodies for three hours at room temperature (see below for
specific antibodies). Slides were then incubated in PBS + Hoechst (1:2000, Invitrogen)
for five minutes at room temperature to stain nuclei and mounted with Mowiol (EMD
Millipore). After staining, coverslips were mounted on slides with Permafluor (Thermo
Scientific) containing Hoechst (1:2000, Invitrogen). Images were captured using a Nikon
C1 confocal mounted on a Nikon Eclipse E800 microscope with a 60× Plan Apo (NA
1.4) oil objective lens, E7-C1 software, and UV, Argon, and He/Ne lasers exciting at 408,
488, and 543 nm and emitting at 404 500–530, and 555–615 nm, respectively.

Antibodies: Primary antibodies used were as follows. Chicken anti-tyrosine hydroxylase
(1:250, Aves), rabbit anti-ki67 (1:200, Novacastra), rabbit anti-CNTFRa (1:30, a
generous gift from Dr. Hermann Rohrer of the Max Planck Institute for Brain Research,
Frankfurt, Germany), mouse anti-3A10 (neurofilament associated antigen, 1:1,
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Development Studies Hybridoma Bank), sheep anti-BrdU (1:100, Biodesign). Secondary
antibodies were donkey anti-rabbit alexa 488 (1:1666, Invitrogen), donkey anti-mouse
cy3 (1:1000, Jackson), donkey anti-rabbit cy3 (1:1000, Jackson), and donkey anti-goat
alexa 488 (1:1000, Invitrogen).

Cell culture: All cells were grown at 37C in 5% CO2. To obtain TH-MYCN tumor cells,
tumors were removed from homozygous TH-MYCN mice at 35 days of age and
mechanically dissociated by triturating in warm Modified Puck’s solution with glucose (a
Ca2+, Mg2+-free balanced salt solution) to produce a single cell suspension. Cells were
then plated on poly-D-lysine (0.5 mg/mL, Sigma) and laminin (0.02 mg/mL, purified in
the Nishi lab from EHS tumors grown subcutaneously in C57Bl6 mice) coated coverslips
(Fisher Scientific) at 50,000 cells per well in a 24-well tissue culture plates (Falcon).
Cells were grown in 20 U/mL penicillin, 20 mg/mL streptomycin, 2mM L-glutamine, and
6 mg/mL glucose in modified L15CO2 supplemented with B27 (1:50, Invitrogen).
Growth factors were added upon plating and consisted of the following – CNTF (5, 1,
0.5, and 0.25 ng/mL, Alomone), BDNF (10 ng/mL, R&D), LIF (10 ng/mL, R&D), 7s
NGF (1 g/mL, Alomone), NT-3 (30 ng/mL, R&D), and GDNF (10 ng/mL, Peprotech).
NHO1S cells (a generous gift from Dr. Michelle Haber of the Children’s Cancer Institute
Australia (Cheng et al., 2007)) were maintained in 10% fetal calf serum, 20 U/mL
penicillin, 20 mg/mL streptomycin, 2mM L-glutamine, and 6 mg/mL glucose in modified
L15CO2. For CNTF experiments, NHO1S cells were plated on poly-D-lysine and
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laminin coated coverslips at 10,000 cells per well in a 24-well plates. Cells were treated
in culture with CNTF (5 ng/mL).

Quantification of process outgrowth and proliferation: Following staining, process
outgrowth and proliferation were quantified with the use of a Nikon Eclipse E800
microscope connected to a computer equipped with StereoInvestigator software (MBF
Bioscience, Williston, VT) in the COBRE Molecular/Cellular Core Facility. The
percentage of ki67 stained cells was quantified using the fractionator program of
StereoInvestigator. Briefly, after creating a defined counting area, the program selected
random views within the area to quantify staining and obtain an estimate of the total
population. Process outgrowth was measured using Neurolucida (MBF Bioscience,
Williston, VT). For each coverslip, 16 random views were selected in which to measure
process length. In order to derive the process length per cell value for each condition, the
total process length from the 16 random views was divided by the cell population (as
determined with StereoInvestigator).

RNA extraction and qPCR: For RNA extraction from NHO1S cells, cells were grown to
confluence in 6-well plates, lysed directly into TRI Reagent (Molecular Research
Center), and RNA was isolated using the manufacturer’s protocol. RNA (1g) was
transcribed to cDNA using superscript III (Invitrogen) and random hexamer priming
(Invitrogen). cDNA was then diluted 1:5 and CNTFRa and 18S RNA expression were
quantified by qPCR with the use of FAM/BHQ labeled primer/Taqman probe mixes
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(ABI) and an ABI 7700 machine in the Molecular Cellular Core operated by the Center
of Biomedical Research Excellence (COBRE) in the Neuroscience department at the
University of Vermont. RNA samples from at least three separate cell cultures were
quantified.

In vivo CNTF treatment and NHO1S tumor growth: NHO1S cells, generously provided
by Dr. Michelle Haber, Children's Cancer Institute Australia for Medical Research,
Randwick, Australia, were grown to confluence in T75 culture dishes. Cells were
injected subcutaneously into the flank of WT 129/SvJ mice (N=12) at 1 million cells per
mouse in 200 L of Matrigel (BD Biosciences). When tumors became palpable, in vivo
treatment with CNTF was begun. Mice received an intraperitoneal injection of either
saline or CNTF (0.2 mg/kg, in saline), daily for 7 days (6 mice per condition). Tumor
growth was quantified by length and width caliper measurement daily by an observer
blinded to the treatment condition. Tumor volume was estimated from length and width
measurements using the formula v = 1.58(/6)(L*W)^(3/2) (Feldman et al., 2009). The
day following the final CNTF or saline injection, final tumor dimensions were measured
and mice were euthanized.

Results
Tumor development in homozygous TH-MYCN mice
Similar to previous observations of tumor formation in TH-MYCN mice on the 129/SvJ
background, 100% of homozygous mice examined formed palpable tumors by an average
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of 49.5 + 0.84 days of age (Table 1). Tumors were large, highly angiogenic, and formed
predominantly in the area of the celiac prevertebral ganglion, as in hemizygous mice
(Chesler et al., 2007). In 2 of 14 mice observed for tumor formation, asymmetrical
enlargement of the superior cervical ganglion was found in addition to abdominal tumor
formation. In one mouse, along with prevertebral tumor formation, a separate tumor
developing along the sympathetic chain was also observed.

CNTF promotes differentiation of TH-MYCN tumor cells in vitro
In order to investigate whether growth factor treatment could influence the phenotype
of tumor cells from TH-MYCN mice, tumors were isolated from 35 day old
homozygous mice, and dissociated tumor cells were treated with brain-derived
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-derived
neurotrophic factor (GDNF), leukemia inhibitory factor (LIF), nerve growth factor
(NGF), neurotrophin 3 (NT-3), or a combination of NGF and NT-3. After 4 days in
culture, treatment with CNTF and LIF, but not other growth factors promoted
approximately a 4-fold increase in process outgrowth (Fig. 2-1A, grey bars, p < 0.01),
as well as a 15% reduction in proliferation, as measured by ki67 staining (Fig. 2-1A,
black bars, p < 0.05). After 3 days in culture, CNTF-treated tumor cells were visibly
more differentiated than untreated cells (Fig. 2-1B and C). Whereas both CNTF and
LIF signaling involves the LIFRb and GP130 receptor signaling subunits, CNTF
signaling requires the additional presence of a CNTFRa subunit, a glycosylphosphoinositide-linked co-receptor commonly expressed in cells of both the
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peripheral and central nervous system (Heller et al., 1996), which binds ciliary
neurotrophic factor (CNTF) (Ip et al., 1993). Therefore, the differentiating effects of
CNTF rather than LIF on TH-MYCN tumor cells were investigated further.

When quantifying CNTF-induced process outgrowth and inhibition of
proliferation after 1, 2, and 3 days of CNTF treatment, we found that CNTF-induced
effects reached significance after 3 days of treatment (Fig. 2-2A and B, p < 0.0001). No
significant changes in cell number were observed over the same time course of CNTF
treatment (Fig. 2-2C), indicating that the effect of CNTF on differentiation and
proliferation was not the result of a selective survival advantage. The effects of CNTF
were concentration-dependent, (p < 0.01), with an EC50 of approximately 0.4 ng/mL for
the effects on neurite outgrowth (Fig. 2-2D) and proliferation (Fig. 2-2E), similar to the
EC50 observed in CNTF-induced decreases in proliferation of embryonic chick
sympathetic neurons (Ernsberger et al., 1989). In addition, we did not observe a
concentration-dependent effect of CNTF on cell number (Fig. 2-2F).

The decrease in cell proliferation observed in the presence of CNTF could result
from either a selective survival advantage provided to non-proliferating cells by CNTF,
or as a result of CNTF promoting actively dividing cells to withdraw from the cell cycle.
In order to distinguish between these two possibilities, we identified dividing cells before
and after CNTF treatment (Fig. 2-3A). Upon plating, bromodeoxyuridine (BrdU) was
added to the culture medium, and cells were treated with or without CNTF. After 24
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hours, the BrdU was washed out, and the media and CNTF were replaced. BrdU
incorporated into the DNA of tumor cells undergoing S-phase during this first 24-hour
period. After an additional 48 hours in culture, tumor cells were fixed and stained for
BrdU (Fig. 2-3B and D), and Ki67, which stains cells dividing at the time of fixation
(Fig. 2-3C and E). Indicating CNTF promotes actively dividing cells to withdraw from
the cell cycle, CNTF treatment caused a ~30% decrease in the percentage of BrdU
positive cells that stained positive for Ki67 (Fig. 2-3E, p < 0.0001).

CNTFR is expressed in tumor cells in vitro and in vivo
In order to distinguish the extent of CNTFR expression in the population of tumor cells
we were treating, we examined CNTFR expression in cultured tumor cells treated with
or without CNTF. CNTFR was highly expressed in cells stained immediately after
plating (Fig. 2-4A and B), and in cells treated with or without CNTF for 3 days (Fig. 24B), with an increase in expression after 3 days in culture. Suggesting the majority of
tumor cells have the ability to differentiate in response to CNTF, CNTFR was
expressed in greater than 70% of cultured tumor cells in all conditions (Fig. 2-4A and B).
Furthermore, despite arising from tissue of the sympathetic nervous system, the majority
of cultured tumor cells lacked staining for tyrosine hydroxylase (TH), the rate-limiting
enzyme in catecholamine synthesis (Fig. 2-4A).

We determined that CNTFR was highly expressed in cultured TH-MYCN tumor
cells. To determine if the receptor is expressed in TH-MYCN tumors in vivo, and
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therefore may respond to in vivo CNTF treatment, we examined expression of the
receptor, as well as other markers, in tumors from TH-MYCN mice. As in cell culture
experiments, tumors were isolated from homozygous mice at 35 days of age. Consistent
with our ex vivo results, CNTFR was also expressed in the majority of tumor cells in
vivo (Fig. 2-4C). Furthermore, qPCR of mRNA isolated from homozygous TH-MYCN
tumors revealed a level of CNTFR expression equivalent to that of the superior cervical
ganglion (Fig. 2-4D). Also consistent with in vitro TH-MYCN tumor cells, as well as a
previous study following tumor development in hemizygous TH-MYCN mice (Chesler et
al., 2007), the majority of TH-MYCN tumors stained strongly for Ki67 in vivo, indicating
a high rate of proliferation in homozygous TH-MYCN tumors (Fig. 2-4E and F).
Furthermore, as we observed in vitro, TH expression was limited in vivo, and found only
in small Ki67-negative clusters throughout the tumor (Fig. 2-4E and F).

Efficacy of CNTF on tumor growth in vivo
After investigating the differentiating effects of CNTF in vitro, we next determined if
CNTF could inhibit TH-MYCN tumor cell growth in vivo. To measure tumor growth
over the course of CNTF treatment, we used a syngenic in vivo tumor growth model
using subcutaneous injection of a cell line derived from TH-MYCN tumors into wild type
129/SvJ mice. In this model, tumor growth can be easily controlled and observed, as it
eliminates waiting for tumor development in homozygous mice, and tumors can be easily
monitored as they grow subcutaneously rather than in the abdominal cavity. Previously,
cell lines had been derived from TH-MYCN tumors by Cheng et. al. (Cheng et al., 2007).
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Screening a few of these cell lines for responsiveness to CNTF, we identified the line
NHO1S to be most representative of primary TH-MYCN tumor cells; it abundantly
expresses the CNTFR receptor and the proliferation marker ki67, expresses low levels
of TH (Fig. 2-5A and B), and differentiates in response to in vitro CNTF treatment (Fig.
2-5C-E). Therefore, NHO1S cells are an appropriate cell line to model in vivo CNTF
treatment of TH-MYCN tumor cells.

To assess the ability of CNTF to inhibit in vivo tumor growth, 1 million NHO1S
cells suspended in 200 L of Matrigel were injected subcutaneously into 12 wild type
129/SvJ mice. When tumors first became palpable, mice began to receive a daily
intraperitoneal injection for 7 days of either saline, or CNTF at 0.2 mg/kg in saline.
Tumor size was monitored daily by an observer blinded to treatment. CNTF treatment
attenuated tumor growth over the course of the experiment. This was marked by a
significant reduction (Fig. 2-5F, p < 0.01) in the fold tumor size (tumor size divided by
starting tumor size) in mice injected with CNTF compared to saline injected mice 7 days
following the first injection. Therefore, in addition to the ability to promote
differentiation in vitro, CNTF is able to attenuate TH-MYCN tumor growth in vivo.
Furthermore, as CNTF is known to cause weight loss in mice (Henderson et al., 1994;
Lambert et al., 2001), mouse weight was measured daily to ensure that CNTF treatment
did not result in an unhealthy reduction in weight. Mice receiving CNTF were observed
to lose a modest 15% of their starting body weight over the course of the experiment
compared with saline injected mice (Fig. 2-5G, p < 0.0001).
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Discussion
The principal finding of this study is that CNTF reduces TH-MYCN tumor cell growth by
reducing cell proliferation and promoting cell differentiation. Of the neurotrophic factors
tested, only the neuropoietic cytokines CNTF and LIF produced this effect. Furthermore,
systemic treatment of animals with CNTF attenuated subcutaneous TH-MYCN-derived
tumor cell growth. Taken together, our data suggest that a further understanding of the
molecular mechanisms involved in neuropoietic cytokine signaling could be beneficial in
developing adjuvant differentiating therapies in neuroblastoma.

Since the discovery of CNTF as a growth factor with the ability to support the
survival of chick embryonic ciliary ganglion neurons (Varon et al., 1979; Lin et al., 1989;
Stockli et al., 1989; Eckenstein et al., 1990), it has been appreciated that CNTF can have
a variety of effects on cells of the nervous system. CNTF treatment promotes survival of
cultured embryonic motor neurons (Arakawa et al., 1990; Oppenheim et al., 1991),
sympathetic (Eckenstein et al., 1990), and sensory neurons (Eckenstein et al., 1990;
Thaler et al., 1994). Treatment of neuroblasts isolated from the sympathetic ganglia of E7
chicken embryos with CNTF promotes the early expression of vasoactive intestinal
peptide (VIP), which is not normally expressed until E10 (Ernsberger et al., 1989).
Furthermore, CNTF induces choline acetyltransferase (ChAT) immunoreactivity in E12
cultured sympathetic neurons, but not at E7 (Ernsberger et al., 1997). In the rat, CNTF
has similar effects, inducing ChAT expression of neonatal superior cervical ganglion
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neurons. In addition, it simultaneously diminishes the expression of tyrosine hydroxylase
(TH) (Saadat et al., 1989). In the central nervous system (CNS), CNTF can support the
survival of cultured hippocampal neurons (Ip et al., 1991), prevents the degeneration of
medial septal neurons (Hagg et al., 1992), and promotes neurogenesis in the forebrain by
increasing neural stem cell proliferation (Emsley and Hagg, 2003).

Similar to the effect on cultured E7 chicken sympathetic neuroblasts, we see that
CNTF inhibits proliferation of primary cultured TH-MYCN neuroblastoma cells.
Although CNTF is able to lead to a ~30% reduction in the number of proliferating cells in
both embryonic sympathetic neurons and TH-MYCN tumor cells (see figure 2-3), many
TH-MYCN tumor cells remain dividing following CNTF treatment (40%) compared to
CNTF treatment in embryonic sympathetic neurons (7%) (Ernsberger et al., 1989). In the
sympathoadrenal progenitor cell line (MAH), which is able to differentiate into
chromaffin-like and sympathetic neuron-like cells, CNTF promotes terminal
differentiation into a neurofilament positive sympathetic phenotype in vivo (Doering et
al., 1995), similar to what we have observed here. Interestingly, in neuroblastoma,
patients whose tumors express high mRNA levels of either CNTF or CNTFR have
improved survival over patients whose tumors have low expression of the two transcripts
(http://home.ccr.cancer.gov/oncology/oncogenomics/).

While tumor cells from the TH-MYCN mouse model of neuroblastoma respond
to CNTF treatment by differentiating, responses of CNTFR-expressing human
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neuroblastoma cells to CNTF remain hard to predict. Consistent with what we observed,
the MYCN-amplified neuroblastoma cell lines LA-N-2 and SK-N-BE, respond to CNTF
treatment with enhanced neurite outgrowth marked by an increased number of tumor
cells with neurites, and increased neurite length (Rossino et al., 1995). However, in the
neuroblastoma cell line SY5Y, from which the CNTFR receptor was originally cloned
(Squinto et al., 1990), treatment with CNTF activates the JAK-STAT pathway
downstream of CNTFR, but does not cause tumor cell differentiation (Rossino et al.,
1995; Halvorsen et al., 1996). Furthermore, although CNTF treatment induces
expression of the neurotrophin receptor TrkA in both GOTO and HTLA230
neuroblastoma cell lines, subsequent treatment with the TrkA ligand NGF results in
proliferation in GOTO cells, but differentiation in HTLA230 cells (Bogenmann et al.,
1998).

We used the TH-MYCN tumor-derived cell line NHO1S to determine whether
CNTF can attenuate TH-MYCN tumor cell growth in vivo. For several reasons, we
believe this cell line to be representative of the primary TH-MYCN tumor cells used in
our in vitro experiments. This cell line is one of 6 cell lines that have been derived from
TH-MYCN tumors (Cheng et al., 2007), and is one of four of these 6 cell lines that have
been derived from homozygous TH-MYCN mice, similar to the primary cells used here.
Furthermore, this cell line, and not other cell lines tested, like primary TH-MYCN tumor
cells, abundantly expresses CNTFR, and differentiates in response to CNTF treatment.
Finally, similar to primary TH-MYCN tumor cells, the majority of NHO1S cells divide in
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culture as indicated by abundant Ki67 staining, while expression of the sympathetic
marker tyrosine hydroxylase is limited to rare cells. Therefore, we feel that NHO1S cells
are an appropriate cell line to model the effect of CNTF on TH-MYCN tumor growth in
vivo.

Despite the encouraging prospect of CNTF as a novel differentiating agent to
limit growth of neuroblastoma tumors, the idea of CNTF as a therapeutic must be
approached with caution. Previously, a recombinant human CNTF (rhCNTF) was tested
in the treatment of amyotropic lateral sclerosis (ALS) following the discovery of the
ability of CNTF to support the survival of motor neurons in vitro (Sendtner et al., 1990)
and in vivo (Mitsumoto et al., 1994). Unfortunately, in addition to proving ineffective at
treating ALS (Bongioanni et al., 2004), CNTF treatment had the adverse side effect of
inducing anorexia and doubling the death rate in those treated at higher doses (Miller et
al., 1996). Consistent with the observed ability of CNTF to cause weight loss in both
human (Ettinger et al., 2003) and animal (Lambert et al., 2001) studies, in the current
study, CNTF-treated mice consistently lost 15% of their body weight over the course of
the experiment, suggesting that CNTF may not be a realistic therapy for neuroblastoma.
Interestingly however, recently a rhCNTF fusion protein was developed (TAT-CNTF),
which is able to rescue rat motor neurons from cell death following sciatic nerve
transection without the typical 20-30% decrease in body weight seen in rhCNTF treated
animals (Rezende et al., 2009). Although the work presented here implicates CNTF as a
novel differentiating agent in neuroblastoma, elucidating the mechanisms involved in
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CNTF-induced differentiation might be of greater therapeutic benefit in the future
treatment of poor prognosis tumors.
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Table 2-1: Tumor development in homozygous TH-MYCN mice
Mouse

Sex

1033-3
1039-1
1042-1
1042-2
1042-3
1048-2
1048-7
1051-2
1051-5
1051-7
1052-1
1052-4
1054-1
1054-2
Average

F
F
M
M
M
M
M
M
M
M
M
M
F
M

Age at tumor
detection
(days)
50
50
54
52
49
48
44
51
51
52
51
50
49
42
49.5 + 0.84

notes

Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor
Abdominal tumor, left SCG 4x larger than right
Abdominal tumor
Abdominal tumor, right SCG 2x larger than left
Abdominal as well as sympathetic chain tumor
Abdominal tumor
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Figure 2-1: Growth factor effects on process outgrowth and proliferation of THMYCN tumor cells in culture
(A) Ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF), which both
activate the CNTF receptor, significantly increase process outgrowth (grey bars, p < 0.01,
ANOVA, n=5) and inhibit proliferation (black bars, p < 0.05, ANOVA, n=5) in tumor
cells derived from TH-MYCN mice after 4 days in vitro compared to control, brainderived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF),
nerve growth factor (NGF), neurotrophin-3 (NT3), and NGF and NT3 (see materials and
methods for treatment concentrations). (B) Confocal image (20x) demonstrating CNTFinduced process outgrowth after 3 days in TH-MYCN tumor cells stained for 3A10, a
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neurofilament associated antigen. Image brightness enhanced to highlight cell processes.
Scale bar = 100mm. Error bars = SEM.

Figure 2-2: CNTF effects are time and concentration dependent
(A) CNTF (closed circles) significantly increases process outgrowth and (B) inhibits
proliferation over control (open circles) after 3 days in culture (p < 0.0001, ANOVA,
n=4). (C) CNTF treatment has no effect on total cell number over the 3 day culture
period. (D) CNTF-induced process outgrowth (p < 0.01, ANOVA, n=4) and (E) decrease
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in proliferation (p < 0.001, ANOVA, n=4) is concentration dependent at 3 days ex vivo.
EC50 for both effects is ~ 0.4 ng/mL. (F) There is no concentration-dependent effect of
CNTF on tumor cell number at 3 days ex vivo. Error bars = SEM.
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Figure 2-3: CNTF promotes TH-MYCN tumor cells that are actively dividing to
withdraw from the cell cycle
(A) Experimental design. On day 1, tumor cells were plated in the presence of
bromodeoxyuridine (BrdU) and treated with or without CNTF. BrdU was washed out
and fresh media and CNTF were added 24 hours later. Tumor cells were fixed and
stained for BrdU and Ki67 after another 48 hours in culture. A similar number of
untreated (B) and CNTF-treated (D) tumor cells are dividing at 1 day in culture indicated
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by incorporation of BrdU. At the 4 day time point a difference in proliferation is
observed between untreated (C) and CNTF-treated (E) tumor cells, indicated by Ki67
staining. A number of CNTF treated tumor cells withdraw from the cell cycle shown by
staining for BrdU, but not Ki67 (arrows in D and E), while the majority of untreated cells
remain dividing at both time points. Scale bar = 10m. (F) Quantification of the
percentage of BrdU cells that stain positive for Ki67 shows a significant decrease in Ki67
staining in CNTF treated tumor cells (p < 0.0001, Student’s t-test, n=4, error bars =
SEM).
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Figure 2-4: Ciliary neurotrophic factor receptor alpha (CNTFR) expression in
TH-MYCN tumor cells in vitro and in vivo
(A) Confocal image (60x) of cultured TH-MYCN tumor cells stained for CNTFR and
TH. Scale bar = 10m. (B) Quantification of CNTFR expression in acutely isolated
cultured tumor cells and tumor cells treated with or without CNTF for 3 days in vitro.
CNTF treatment has no effect on CNTFR expression. (C) Confocal image (60x) of a
tumor section stained for ciliary neurotrophic factor receptor alpha (CNTFR
tyrosine hydroxylase (TH, green). Similar to cultured tumor cells, tumor cells abundantly
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express the CNTF receptor in vivo, while few cells express TH. Scale bar = 10m. (D)
mRNA expression of CNTFR in superior cervical ganglion (SCG) and tumor tissue.
CNTFR is expressed in tumor tissue at levels equivalent to that of normal sympathetic
tissue. (E) Confocal image (20x) of a tumor section stained for Ki67 (red) and tyrosine
hydroxylase (TH, green) isolated from a 35-day old homozygous TH-MYCN mouse.
Scale bar = 100m. (F) Confocal image (60x) shows abundant proliferation, indicated by
Ki67 staining, with isolated non-proliferating TH-expressing tumor cells scattered
throughout the tumor, consistent with Ki67 and TH expression in vitro. Scale bar =
100m.
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Figure 2-5: NHO1S cells differentiate in response to CNTF in vitro and CNTF
treatment attenuates NHO1S tumor cell growth in vivo
(A-B) Similar to primary TH-MYCN tumor cells, NHO1S cells abundantly express
CNTFR (red stain in A) and Ki67 (red stain in B), while TH expression is more limited
(green stain in A and B). (C-E) Like primary TH-MYCN tumor cells, NHO1S cells
differentiate in response to in vitro CNTF treatment (p < 0.01, Student’s t-test, n=4).
Scale bar = 100m and applies to all images. (F) Intraperitoneal injection of CNTF (0.2
mg/kg daily, black squares) attenuates subcutaneous tumor growth compared to saline
injected mice (black circles) as measured by change in fold tumor size over the course of
the experiment (p < 0.01, ANOVA, n=6). (G) Confirming CNTF was biologically active
in vivo, CNTF treated mice lost an average of 15% of their starting weight over the
course of the experiment (p < 0.0001, ANOVA, n=6). Error bars = SEM.
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Abstract
Neuroblastoma arises from sympathoadrenal progenitors of the neural crest. Expression
of the neurotrophin receptor TrkB and its ligand, brain-derived neurotrophic factor
(BDNF), is correlated with poor prognosis. Although activated TrkB signaling promotes
a more aggressive phenotype in established neuroblastoma cell lines, whether TrkB
signaling is sufficient to transform neural crest derived cells has not been investigated.
To address the role of TrkB signaling in malignant transformation, we removed two
immunoglobulin-like domains from the extracellular domain of the full length rat TrkB
receptor. This construct (termed ΔIgTrkB) activates phosphorylated Erk1/2 in the
absence of the TrkB ligand BDNF. In the pheochromocytoma- derived cell line PC12,
ΔIgTrkB promotes differentiation by stimulating process outgrowth; however, in the rat
neural crest derived cell line NCM-1, ΔIgTrkB signaling produces a markedly
transformed phenotype characterized by increased proliferation, anchorage-independent
cell growth, anoikis resistance, and matrix invasion. Furthermore, expression of
ΔIgTrkB leads to upregulation of many transcripts encoding cancer-associated genes
including cyclind1, twist1, and hgf, as well as downregulation of tumor suppressors such
as pten, and rb1. In addition, ΔIgTrkB NCM-1 cells show a 21-fold increase in mRNA
for MYCN, the most common genetic marker for a poor prognosis in neuroblastoma.
When injected into NOD SCID mice, control NCM-1 cells fail to grow while ΔIgTrkB
NCM-1 cells form rapidly growing and invasive tumors necessitating euthanasia of all
mice by 15 days post injection. In summary, these results indicate that activated TrkB
signaling is sufficient to promote the formation of a highly malignant phenotype in
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neural crest derived cells.

Introduction
Neuroblastoma, a pediatric malignancy arising from sympathoadrenal precursors from
the neural crest (Hoehner et al., 1996), is a cancer typified by its heterogeneity of disease.
Disease course in neuroblastoma can range anywhere from patients presenting with
metastatic disease that will spontaneously regress with support treatment alone (stage
4S), to localized favorable tumors, to cases of aggressive neuroblastoma, in which
children will often relapse following treatment despite the most intensive chemo- and
adjuvant therapy (Maris et al., 2007).

This heterogeneity in disease course is correlated with a number of different
factors including Trk receptor expression (Brodeur, 2003). Trk receptors are important
in normal sympathetic development; for example, TrkA, the high affinity receptor for
nerve growth factor (NGF), promotes target-dependent survival of sympathetic neurons
by preventing programmed cell death (Miller and Kaplan, 2001; Reichardt, 2006).
Following this model of development, neuroblastoma tumors that express TrkA have a
favorable prognosis (Nakagawara, 1998). In contrast, many MYCN amplified, poor
prognosis neuroblastomas express TrkB, resulting in tumors that are often highly
aggressive and eventually fatal (Schramm et al., 2005). There is also a developmental
basis for this: TrkB is transiently expressed in sympathetic progenitors prior to the onset
of TrkA expression (Straub et al., 2007), and when stimulated with BDNF, the TrkB
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expressing cells proliferate in cell culture (Reiff et al.; Straub et al., 2007) and in vivo
(Straub and Nishi, unpublished observations).

An important question is whether TrkB expression is a marker of poor prognosis,
or whether active TrkB signaling is directly responsible for the aggressive nature of poor
prognosis neuroblastoma. Supporting a causal role for TrkB signaling, concomitant
expression of full length TrkB and BDNF leads to autocrine signaling enhancing tumor
cell survival and invasiveness (Matsumoto et al., 1995). Conversely, a truncated TrkB
isoform lacking the tyrosine kinase domain is commonly expressed in more benign and
differentiated tumors such as ganglioneuroblastomas (Brodeur et al., 1997).
Furthermore, treatment of TrkB-expressing SMS-KCN neuroblastoma cells with BDNF
enhances cell survival in serum free media (Nakagawara et al., 1994). Similarly BDNF
treatment of SH-SY5Y cells either transfected with TrkB or induced to express TrkB by
retinoic acid have enhanced survival in conditions of limited growth factors (Matsumoto
et al., 1995; Kim et al., 1999), increased resistance to chemotherapeutics (Scala et al.,
1996; Ho et al., 2002; Jaboin et al., 2002), increased production of angiogenic factors
(Eggert et al., 2002; Nakamura et al., 2006), and enhanced invasion (Matsumoto et al.,
1995). Therefore, TrkB signaling contributes to the aggressiveness of poor prognosis
neuroblastoma, but it is still unknown whether TrkB signaling alone can transform cells
of the neural crest lineage.
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To determine if constitutively active TrkB signaling is sufficient to transform
cells, we created a mutant form of the TrkB receptor by removal of two immunoglobulinlike ligand binding domains. We stably transfected this construct into the neural crestderived cell line NCM-1 to investigate its transforming capacity. Constitutive TrkB
signaling proved to be highly transforming in NCM-1 cells in vitro, and strongly
tumorigenic in vivo. Our results suggest aberrant TrkB signaling alone is sufficient to
give rise to the highly aggressive and fatal tumors seen in TrkB-expressing
neuroblastoma.

Results
Removal of two immunoglobulin-like domains renders TrkB constitutively active
To better understand the role of TrkB signaling in neuroblastoma pathogenesis we
created a constitutively active form of the TrkB receptor. Previous studies have shown
the TrkA tyrosine kinase receptor can be rendered constitutively active by removal of the
two immunoglobulin-like (Ig-like) domains in the extracellular region of the receptor
(Arevalo et al., 2000). Therefore, we created this construct (ΔIgTrkB; Fig. 3-1) and
stably transfected HEK293 cells. Additionally, a separate stably transfected HEK293
line was created by transfection with a wild type (WT) TrkB receptor construct.
Expression of the receptor in both TrkB expressing cell lines was confirmed, with
ΔIgTrkB displaying a lower molecular weight than WT TrkB (Fig. 3-2A). As expected,
a marked increase of phosphorylated Erk 1/2 was observed only when WT TrkB
HEK293 cells were treated with BDNF. In contrast, elevated p-Erk 1/2 was observed in
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both BDNF treated and untreated ΔIgTrkB HEK293 cells (Fig. 3-2A), albeit at
significantly lower levels when compared to the BDNF-stimulated WT TrkB (Fig. 3-2B).
Therefore, we tested whether this level of constitutive signaling by ΔIgTrkB was
sufficient to promote downstream biological effects.

ΔIgTrkB promotes neurite outgrowth in PC12 cells
PC12 cells are a well-known model of nerve growth factor (NGF) induced neuronal
differentiation via TrkA (Greene and Tischler, 1976; Kaplan et al., 1991), and TrkB
transfected PC12 cells differentiate in response to BDNF (Jian et al., 1996). PC12 cells
were transiently transfected with ΔIgTrkB or GFP control construct, and two days later
treated with or without 7sNGF (1µg/mL). After 6 days, cells were fixed and stained for
either TrkB or GFP to identify transfected cells. Cells transfected with ΔIgTrkB had a 6fold increase in the number of neurite bearing cells over GFP transfected cells in the
absence of NGF (Fig. 3-3A-C). ΔIgTrkB-induced neurite outgrowth is equivalent to that
of NGF through TrkA, as there was no difference in the number of neurite bearing cells
between ΔIgTrkB or GFP transfected cells in the presence of NGF (Fig. 3-3D).

ΔIgTrkB enhances proliferation in the neural crest derived cell line NCM-1
NCM-1 is an immortalized, multipotent cell line with the ability to generate
sympathoadrenal precursors (Lo et al., 1991). To determine if constitutive TrkB
signaling promotes proliferation or differentiation in NCM-1 cells, we transfected cells
with ΔIgTrkB (Fig. 3-S2). Stable ΔIgTrkB NCM-1 transfectants had a morphology
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marked by more rounded cell bodies compared with the bipolar morphology of nontransfected NCM-1 cells (Fig. 3-4A-F). Furthermore, ΔIgTrkB NCM-1 cells grew to
confluency more quickly than WT NCM-1 cells (Fig. 3-4A-F).

In order to quantify the apparent increase in proliferation, cells were counted
using the vital fluorescent dye calcein AM (Saulnier Sholler et al., 2006). We noted a
2.5-fold increase in cell number after 4 days in ΔIgTrkB NCM-1 cells compared with
WT NCM-1 cells (p < 0.0001, Fig. 3-4I). Further supporting enhanced proliferation,
western blot analysis for phosphorylated histone H3, a protein preferentially expressed in
dividing cells, demonstrated in IgTrkB NCM-1 cells a 1.5-fold increase compared with
WT cells (p < 0.05, Fig. 3-4G-H). To confirm that this phenotype did not arise from a
random insertion of our construct disrupting a tumor suppressor, five additional parent
lines were established. All showed a significant increase in cell number after 4 days in
vitro (Fig. 3-S3, p < 0.001). Additionally, treatment with the pan-Trk kinase inhibitor
K252a abolished ΔIgTrkB-mediated proliferation, resulting in calcein AM fluorescence
equivalent to WT NCM-1 cells (Fig. 3-4J). This demonstrated that TrkB kinase activity
is required for the observed enhanced proliferation. Therefore, constitutive signaling
through ΔIgTrkB promotes a higher rate of proliferation in the neural crest-derived
NCM-1 cell line.

ΔIgTrkB transforms NCM-1 cells
Although ΔIgTrkB signaling increases the rate of growth of NCM-1 cells, enhanced
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proliferation alone is not sufficient to consider a cell transformed. For example, healthy
cells require attachment to a surface to divide, and the loss of this requirement in
transformed cells is known as anchorage-independent cell growth. To determine if
ΔIgTrkB expression confers anchorage independent cell growth, cells were cultured
suspended in soft agar. After one week, there was a 25-fold increase in colony formation
in ΔIgTrkB transfected cells (p < 0.001, Fig. 3-5A-C).

Normally, when cells grown in culture detach from the culture surface they
undergo anoikis, or detachment-induced apoptosis; however, cancer cells escape anoikis.
To determine if ΔIgTrkB allows NCM-1 cells to become anoikis resistant, the number of
live cells in the medium collected from transfected and untransfected cells was
quantified. We observed a 4-fold increase in the number of live cells in the media from
ΔIgTrkB NCM-1 cultures compared with WT NCM-1 (p < 0.05, Fig. 3-5D), indicating
ΔIgTrkB promotes anoikis resistance in NCM-1 cells.

Another important characteristic of malignant transformation is the ability of cells
to migrate to and invade surrounding tissues and blood vessels. To investigate whether
ΔIgTrkB expression enhances migration and invasion we used a radial migration assay
known as ‘the donut assay’ (McKenzie et al., 2011). In this assay, cells are limited to a
restricted area by silicone donut. Following donut removal, the number of cells
migrating radially from the confined area are quantified. Neural crest cells are
intrinsically migratory, as during development they must migrate from the neural tube to
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their final locations throughout the body. In light of this, we did not find any significant
difference in the total number of migrating cells outside the originally confined area after
24 hours (Fig. 3-6A-C, E-G, J). However, there was a significant increase in the area
within which migrated cells could be found, indicating that in our assay ΔIgTrkB NCM-1
cells migrated farther compared with WT NCM-1 cells (p < 0.0001, Fig. 3-6D, H-I).

Although neural crest cells are intrinsically migratory, they are not intrinsically
invasive. Invasion requires the ability of cells to degrade extracellular matrix in order to
migrate. To investigate invasion, a layer of matrigel was overlaid on the cells in a new
set of experiments. Addition of matrigel led to a reduction in the number of cells that
traveled outside the originally confined area for both cell types (Fig. 3-6J vs. 3-6T). We
observed that ΔIgTrkB NCM-1 cells had an enhanced ability to invade extracellular
matrix that was marked by a 2.5-fold increase in the number of invading cells after 24
hours (p < 0.05, Fig. 3-6K-M, O-Q, T). Furthermore, ΔIgTrkB NCM-1 cells invaded
across a greater distance into the matrigel as indicated by a 2.5-fold increase in total area
invaded by ΔIgTrkB NCM-1 cells compared with WT (p < 0.05, Fig. 3-6N, R, S).

ΔIgTrkB enhances cancer related gene expression in NCM-1 cells
To identify genes contributing to the transformed phenotype in ΔIgTrkB NCM-1 cells,
we analyzed transcripts using a targeted qPCR array for cancer pathway genes. This
analysis revealed that expression of ΔIgTrkB increases transcript levels for a number of
cancer promoting genes (Table 3-1), as well as decreases the expression of tumor
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suppressor genes (Table 3-2). Consistent with the enhanced proliferation of ΔIgTrkB
NCM-1 cells compared with WT cells, we detected a 436-fold increase in transcripts
levels (p < 0.0001) as well as significantly enhanced protein levels (p < 0.05, Fig. 3-S4)
for the cell cycle regulatory gene cyclind1. Furthermore, upregulation of twist1 (39-fold,
p < 0.0001) and hepatocyte growth factor (hgf, 29-fold, p < 0.0001), two genes known to
play important roles in promoting invasion and metastasis (Li et al.; Hecht et al., 2005), is
consistent with the enhanced invasive capacity of ΔIgTrkB NCM-1 cells. Moreover,
expression of ΔIgTrkB in NCM-1 cells significantly downregulates expression of the
tumor suppressors pten (-1.71-fold, p<0.001) and rb1 (-1.77-fold, p<0.001). Therefore,
mRNA expression in ΔIgTrkB NCM-1 cells is consistent with the highly transformed
phenotype of the cells.

c-Met inhibition abolishes enhanced proliferation in ΔIgTrkB NCM-1 cells
Previous work has implicated the hepatocyte growth factor (HGF) / c-Met signaling
pathway in promoting neuroblastoma cell invasiveness (Hecht et al., 2005). In ΔIgTrkB
NCM-1 cells hgf levels were upregulated 29-fold. Additionally, c-Met was also
upregulated 1.5-fold (p < 0.0001), suggesting that this pathway may be important in the
transformed phenotype mediated by constitutive TrkB signaling. Furthermore, while
K252a was first characterized as a pan-Trk kinase inhibitor, it has also been shown to
inhibit a number of other tyrosine kinases including c-Met (Morotti et al., 2002). This
suggested that our K252a proliferation inhibition results may have been due to c-Met
inhibition. In order to determine if the c-Met signaling pathway mediates ΔIgTrkB-
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induced proliferation, WT and ΔIgTrkB NCM-1 cells were grown in the specific c-Met
inhibitor SU11274 and proliferation was assessed. Treatment with SU11274 (1 µM)
abolished the increased proliferation of ΔIgTrkB NCM-1 cells, resulting in a 4 day
growth curve that mirrored that of WT NCM-1 cells treated with, or without inhibitor
(Fig. 3-7). Treatment with vehicle (DMSO) alone had no effect on the enhanced
proliferation of ΔIgTrkB NCM-1 cells (Fig. 3-7, p < 0.0001), verifying that this effect
was specific to the inhibitor. These results show that c-Met signaling is required for the
enhanced proliferation of IgTrkB NCM-1 cells.

ΔIgTrkB upregulates expression of the poor prognosis marker mycn in NCM-1 cells
To determine if the transformation of NCM-1 cells by ΔIgTrkB influences the expression
of mycn, a marker of poor prognosis in neuroblastoma that was not included in the cancer
pathway array, we compared transcript levels in WT and ΔIgTrkB NCM-1 cells by
qPCR. We found a 21-fold increase in mycn levels in ΔIgTrkB NCM-1 cells compared
with WT NCM-1 cells (p < 0.01, Table 3-1). Therefore, aberrant TrkB signaling in the
neural crest derived NCM-1 cell line is sufficient to upregulate expression of the
neuroblastoma poor prognosis marker MYCN.

ΔIgTrkB NCM-1 cells form rapidly growing and aggressive tumors in vivo
To determine if ΔIgTrkB expression would enhance the ability of NCM-1 cells to form
tumors in vivo, NOD-SCID mice were injected subcutaneously with 1 million ΔIgTrkB
or WT NCM-1 cells suspended in matrigel. One week following NCM-1 cell injection,
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tumors became palpable in mice injected with ΔIgTrkB cells (Fig. 3-8A, p < 0.01), and
all ΔIgTrkB NCM-1 injected mice were sacrificed by 15 days post-injection due to tumor
burden (Fig. 3-8B, p< 0.01). WT NCM-1 injected mice remained tumor free throughout
the experiment (Fig. 3-8). Monitoring tumor size daily, ΔIgTrkB NCM-1 tumors grew
rapidly, measuring an estimated 8 cm3 by 2 weeks after injection, while WT NCM-1
cells failed to grow (Fig. 3-8C, p < 0.0001). Upon removal, ΔIgTrkB NCM-1 cell tumors
were large and vascularized with an average wet weight of 4.5 grams (Fig. 3-8E-F).
ΔIgTrkB tumors grew at a rapid pace and were also highly invasive, invading the
vertebrae and compressing the spine in one mouse. This resulted in bilateral hind limb
paralysis by 10 days following injection (Fig. 3-8G-H). Tumor tissue showed a
histology that consisted of many closely packed cells with scant cytoplasm and little
extracellular stroma, reminiscent of aggressive, poor prognosis neuroblastoma (Fig. 38D). Furthermore, a separate injection of only 100 cells formed tumors in 3/3 mice
within 21 days, demonstrating that ΔIgTrkB NCM-1 cells are highly tumorigenic.
Therefore, constitutive TrkB signaling is sufficient to transform the neural crest derived
cell line NCM-1 into highly aggressive tumor cells in vivo.

Discussion
We provide evidence that constitutive TrkB signaling is sufficient to transform a neural
crest cell line into a carcinogenic phenotype marked by enhanced proliferation,
anchorage independent cell growth, anoikis resistance, migration and invasion, and
tumorigenesis. Furthermore, we noted transcriptional deregulation as a consequence of
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aberrant TrkB signaling, such as upregulation of MYCN, a gene whose amplification is
significantly correlated with both the expression of TrkB/BDNF in neuroblastoma, as
well as a more aggressive tumor phenotype and poor prognosis. Taken together, our data
suggest that aberrant TrkB signaling in the developing sympathoadrenal lineage may be
sufficient to promote neuroblastoma formation.

Although Trk receptors are now known to be the high affinity receptors for the
neurotrophin family of growth factors, the first Trk receptor (TrkA) was discovered as an
oncogene. Named the “tropomyosin-receptor kinase” (Trk), the gene was isolated from a
colon carcinoma, and resulted from the fusion of a truncated tropomyosin and the
tyrosine kinase domain of TrkA that rendered the kinase constitutively active (MartinZanca et al., 1986). Subsequently, the TrkB receptor was discovered and found to be the
high affinity receptor for BDNF, and when co-expressed in 3T3 fibroblasts with BDNF,
receptor activation promoted proliferation and anchorage-independent cell growth (Glass
et al., 1991; Klein et al., 1991). In epithelial cells, TrkB has been shown to promote
anoikis resistance by conferring cells with the ability to grow in suspension (Douma et
al., 2004), whereas TrkB signaling enhances invasion in a number of cell lines including
neuroblastoma (Matsumoto et al., 1995; Hecht et al., 2005; Cimmino et al., 2009), colon
cancer (Yu et al., 2006), head and neck squamous cell carcinoma (Kupferman et al.,
2010), non-small cell lung cancer (Zhang et al., 2010), and epithelial (Geiger and Peeper,
2007). TrkB signaling in vivo promotes tumor growth in neuroblastoma (Eggert et al.,
2002), epithelial (Douma et al., 2004), and transitional cell carcinoma (Huang et al.,
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2010). However, none of these studies determined whether TrkB signaling in neural
crest-derived cells is sufficient to promote an aggressive, fully transformed phenotype.

Transformation of rat NCM-1 cells by ΔIgTrkB activates the expression of genes
also seen in poor prognosis neuroblastoma including cyclind1, twist1, hgf, and mycn.
CYCLIND1 is known to be selectively amplified in poor prognosis neuroblastoma tumors
(Molenaar et al., 2011), and this heightened expression is not simply a general
characteristic of any cancer, but is more elevated in neuroblastoma compared to many
other tumors (Molenaar et al., 2011). Further supporting ΔIgTrkB NCM-1 cells as a
model for poor prognosis neuroblastoma, TWIST1 has been shown to be expressed in
100% (7/7) of MYCN amplified tumors, but only 11% (2/18) of non-MYCN amplified
tumors (Valsesia-Wittmann et al., 2004). In MYCN amplified neuroblastoma cell lines,
TWIST1 expression ranged from 16-164 fold that of non-MYCN amplified lines
(Valsesia-Wittmann et al., 2004), consistent with the 39-fold increase in twist1
expression we observed in ΔIgTrkB NCM-1 cells. This suggests a specific cooperation
of TWIST1 and MYCN in neuroblastoma, TWIST1 inhibits expression of the tumor
suppressor P53 (Valsesia-Wittmann et al., 2004), which allows MYCN-amplified tumors,
and in the case of our study, ΔIgTrkB NCM-1 cells, to escape P53-dependent apoptosis.
In this study we noted a 29-fold upregulation of hgf, and a 1.5-fold upregulation of the
HGF receptor c-met in ΔIgTrkB NCM-1 cells. Although increased c-Met signaling is a
common occurrence in many types of cancer (Liu et al., 1992; Furukawa et al., 1995;
Ramirez et al., 2000; Tokunou et al., 2001; Lengyel et al., 2005), the only other study to
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demonstrate TrkB-mediated upregulation of c-Met signaling was in neuroblastoma cells,
where TrkB expression led to 5- to 10-fold increases in HGF, and 40- to 400-fold
increases in c-Met mRNA levels. This same study found TrkB-expressing primary
neuroblastoma tumor samples to have coordinated expression of HGF and c-Met (Hecht
et al., 2005).

ΔIgTrkB NCM-1 cells display an enhanced ability to form rapidly growing and
invasive tumors, compared to oncogenes expressed in other cell lines. NCM-1 cells were
isolated from rat embryos and immortalized by transduction with a v-myc-containing
replication-deficient retrovirus (Lo et al., 1991). Although v-myc expression itself can
be transforming (Ramsay et al., 1990), this is not the case in NCM-1 cells because of
their ability to differentiate (Lo et al., 1991), and because they do not grow in soft agar,
or form tumors in vivo. We observed that the addition of constitutive TrkB signaling
resulted in dramatically transformed cells that form large invasive tumors. Similar in
vivo tumor growth was seen in a v-myc immortalized rat fibroblast cell line expressing
oncogenic BCR-ABL (Lugo and Witte, 1989), however this study injected 50% more
cells to initiate tumorigenesis (1.5 million as opposed to 1 million injected here). In
another study, expression of the oncogene BCL2 led to in vivo tumorigenesis in a rat L6
myoblast cell line expressing v-myc, but tumors formed only after 10 weeks (Screaton et
al., 1997). Recently, Schulte et. al. (2012) found that JoMa1 neural crest progenitor cells
(maintained in an undifferentiated state by inducible c-myc expression) can be
transformed by an oncogenic variant of the ALKF1174L, and in 2 out of 6 mice were able
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to form tumors in vivo that were lethal to the mouse by 48 days following injection of 20
million cells (Schulte et al., 2012). Thus, ΔIgTrkB is considerably more oncogenic in
vivo than ALKF1174L. ΔIgTrkB NCM-1 tumors were also highly invasive. In one
mouse, tumor cell invasion of the spine, caused spinal cord compression and bilateral
paralysis. This observation is reminiscent of cases of human neuroblastoma, where
cancer can extend into the spinal foramina causing nerve root and spinal cord
compression in patients with paraspinal tumors (Plantaz et al., 1996; De Bernardi et al.,
2001; De Bernardi et al., 2005). In total, 5% of all neuroblastoma patients present with
signs related to cord impingement (Plantaz et al., 1996; De Bernardi et al., 2001).

The highly aggressive behavior observed in ΔIgTrkB NCM-1 cells is not likely
due solely to upregulation of MYCN. Because MYCN amplification is the most consistent
genetic alteration seen in poor prognosis neuroblastoma (Seeger et al., 1985), it has been
hypothesized that MYCN overexpression is largely responsible for the aggressive
phenotype of these tumors. The 21- fold upregulation of mycn mRNA observed in
ΔIgTrkB NCM-1 cells is consistent with the increased mRNA expression observed in
MYCN-amplified neuroblastoma tumors and cell lines, which has been observed to range
anywhere from 20- to 80-fold (Schwab et al., 1984). Furthermore, while MYCN
amplification is present in only 25% of neuroblastomas (Brodeur et al., 1986), 70% of
these tumors express TrkB and BDNF (Nakagawara et al., 1994). Therefore, in the
proper developmental context, active TrkB signaling may drive MYCN amplification in
MYCN/TrkB/BDNF expressing neuroblastomas. While other studies suggest MYCN
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overexpression itself is sufficient to drive neuroblastoma formation, the subsequent
tumors formed are slower growing and more spatially-confined than the tumors we
observed from ΔIgTrkB NCM-1 cells. For example, in the TH-MYCN transgenic mouse,
targeted expression of MYCN to the neural crest lineage by driving expression with the
tyrosine hydroxylase promoter is tumorigenic (Weiss et al., 1997). However, unlike the
human form of the disease where TrkB and BDNF are highly expressed in the majority of
MYCN amplified tumors, TH-MYCN tumors highly express BDNF, but lack TrkB
expression (DeWitt and Nishi, unpublished data). Also, MYCN amplification is unlikely
to be the initiating event in human neuroblastoma, as amplification of this gene is not
known to occur in normal mammalian cells (Tlsty, 1990; Wright et al., 1990; Fischer et
al., 2012). In addition, JoMa1 neural crest cells overexpressing MYCN form highly
variable, slow growing tumors with mice surviving anywhere from 43-123 days (Schulte
et al., 2012). Thus our results suggest that TrkB upregulates MYCN in parallel with
additional pathways that contribute to a highly aggressive, carcinogenic phenotype. This
underscores the importance of the development of therapies targeting TrkB signaling,
such as lestaurtinib (CEP-701) (Minturn et al., 2011).

Materials and methods
Constructs: Using a full-length rat trkb (WT trkb) construct generously provided by Dr.
Moses Chao, New York University, NY, NY, we used site-directed mutagenesis to
convert a single base at base pair 1814 into a pst1 site. Both Ig-like domains could then
be removed by pst1 (New England Biolabs, Ipswich, MA) digestion due to another pst1
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site at base pair 1233. For HEK293 experiments ΔIgtrkb and WT trkb were cloned into
pcDNA3.1 (Invitrogen, San Diego, CA). For PC12 experiments ΔIgtrkb was cloned into
an inducible vector (pTRE-tight) and transfected into an rTTa-expressing PC12 Tet-on
cell line (Clontech, Mountain View, CA). For NCM-1 experiments ΔIgtrkb was cloned
into a piggyBAC transposon-transposase vector (pmhyGENIE-3) containing a DsRed tag
and hygromycin selection gene (Urschitz et al., 2010). NCM-1 cells were transfected
with a GFP-expressing control piggyBAC vector (pmGENIE-3) to establish a control cell
line for in vivo experiments.

Cell Culture: Cells were grown at 37°C in 5% CO2. HEK293 and NCM-1 cells were
maintained in 10% (v/v) fetal bovine serum, 20 U/mL penicillin, 20 mg/mL
streptomycin, 2mM L-glutamine, and 6 mg/mL glucose in modified L15CO2 (Mains and
Patterson, 1973). Serum for PC12 cells was 5% fetal bovine serum and 5% heatinactivated horse serum.

Transfections: HEK293 and PC12 cells were transfected using JetPEI (Polyplus
transfection, Illkirch, France). Stably-transfected HEK293 cells were established by
G418 (Sigma, St. Louis, MO) selection. NCM-1 cells were transfected using XtremeGENE 9 (Roche, Indianapolis, IN) and stable cells were established by hygromycin
(Sigma) selection.

Western blotting: Cells were seeded at 250,000 per well in 6-well plates. For HEK293
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experiments cells were serum-starved for 24 hours, treated with, or without BDNF
(100ng/mL, R&D Systems) for 1 hour and then collected for SDS PAGE by direct lysis
into 100 µL of 1x SDS sample buffer + 5% β−Mercaptoethanol (βMe). Samples were
run on an 8% polyacrylamide gel and then transferred to a nitrocellulose membrane
(Osmonics, Inc., Minnetonka, MN) overnight at 4°C at 30 volts (Hoefer Scientific
Instruments, San Francisco, CA). Blots were incubated with primary antibodies
overnight at 4°C, washed 4x for 10 minutes, and then incubated in appropriate secondary
antibodies for 1 hour at room temperature. Primary antibodies used were: goat antiTrkB (1:1000, R&D Systems); rabbit anti-p-Erk1/2 (1:500, Cell Signaling, Boston, MA);
goat anti-β actin (1:1000, Santa Cruz, Santa Cruz, CA); rabbit anti-Phospho-Histone H3
(1:500, Cell Signaling); and mouse anti-Cyclin D1 (1:1000; Cell Signaling). Secondary
antibodies used were donkey anti-goat 700 (Rockland, Gilbertsville, PA); donkey antirabbit 800 (Rockland); and donkey anti-mouse 800 (Rockland) all at 1:10 000. Blots
were analyzed with an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE).

PC12 neurite outgrowth: PC12 cells were plated on poly-D-lysine (0.5 mg/mL, Sigma)
and laminin (0.02 mg/mL, purified in the Nishi lab from EHS tumors grown
subcutaneously in C57Bl6 mice) coated coverslips at 50,000 cells per well. The day after
plating, cells were transfected with either an inducible GFP or the inducible ΔIgtrkb
construct and allowed to recover for 48 hrs prior to treatment with doxycline (1 µg/mL,
Sigma) and 7s NGF (1 µg/mL, Alomone, Jerusalem, Israel). Coverslips were fixed 30
min in Zamboni's fixative (4% (w/v) paraformaldehyde, 15% (v/v) picric acid in 0.1 M
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sodium phosphate buffer, pH 7.4) and processed for immunocytochemistry as previously
described (Hruska and Nishi, 2007). Primary antibodies were: goat anti-TrkB (1:1000,
R&D Systems); chicken anti-GFP (1:1000, Aves, Tigard, OR). Secondary antibodies
were: donkey anti-goat alexa 488 (1:1000, Invitrogen) and goat anti-chicken alexa 488
(1:1000, Invitrogen). A Nikon Eclipse E800 microscope connected to a computer
equipped with StereoInvestigator software (MBF Bioscience, Williston, VT) was used to
count neurite-positive PC12 cells. A neurite was defined as a process with a length at
least twice the cell’s soma size.

Calcein AM: NCM-1 cells were plated on poly-D-lysine coated 96 well plates at 200
cells per well in 100 µL of media and viability was assessed using 2 µM calcein AM
(Molecular Probes, Eugene, OR) with a FLUOstar Galaxy (BMG, Cary, NC) fluorescent
microplate reader. Each condition was replicated in a minimum of 8 wells on the same
plate. For K252a (Merck, Darmstedt, Germany) and c-Met inhibitor (SU11274, Merck)
treatments, inhibitors (50 nM and 1 µm, respectively) were added at the time of plating.

Soft agar assay: 6-well plates were coated with 0.5% agar (Affymetrix, Santa Clara, CA)
in growth medium. After the base layer had solidified, NCM-1 cells suspended in 0.35%
agar were plated on top of the base layer at 1000 cells per well. Cells were fed by adding
0.5 mL of media to the top of each well every 3 days. Colony number was quantified
after 7 days.
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Anoikis assay: To quantify anoikis, medium was collected 3 days after cultures achieved
confluence and the number of live cells growing in the media was quantified by trypan
blue (0.08%, Sigma) exclusion and a hemocytometer.

Migration and invasion: The ‘donut assay’ for migration and invasion was used as
described (McKenzie et al., 2011). Cells (10,000) were plated on poly-D-lysine- and
laminin-coated coverslips in a 10 µL volume. Initial images were acquired through a 2X
PlanApo objective on a Nikon Eclipse TE-2000E inverted microscope. A second set of
images acquired after 24 hours were compared and analyzed using the default settings of
a custom written ImageJ macro (McKenzie et al., 2011). With the macro, area migrated /
invaded was quantified by measuring the area between the outer bound of the farthest
migrating / invading cells after 24 hours and the bound of the cells directly after gasket
removal.

RNA extraction and qPCR array: Cells were grown to confluence in 6-well plates, lysed
directly into TRI Reagent (Molecular Research Center, Cincinnati, OH), and RNA was
isolated using the manufacturer’s protocol. RNA quality and genomic DNA
contamination were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Reverse transcription and Cancer Pathways qPCRarray plate
(SABiosciences, Valencia, CA) analysis was performed at the VT Cancer Center DNA
Analysis Facility using a RT2 First Strand kit (SABiosciences, Valencia, CA). Three
arrays each testing an independently isolated RNA sample were analyzed for each cell
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line. Mycn expression transcription levels were evaluated by reverse transcription of 1 µg
of RNA transcribed to cDNA using (Superscript III, Invitrogen) and subsequent Taqmanbased qPCR (ABI).

In vivo: Mice were housed in an NIH and AALAC approved animal facility at UVM and
treated following an approved IACUC protocol. Cells were injected subcutaneously into
flanks of NOD-SCID mice at 106 cells per mouse in 200 µL of matrigel (BD
Biosciences). Four mice were injected per cell line. When tumors became palpable,
tumor growth was quantified initially every other day, and then daily when it became
apparent TrkB tumors were fast growing. Tumor volume was estimated from length and
width measurements by the formula v = 1.58(π/6)(L*W)^(3/2) (Feldman et al., 2009). To
examine the lower limits of the tumorigenic potential of ΔIgTrkB NCM-1 cells, 100 cells
in 200 µL of matrigel were injected into 3 NOD-SCID mice that were then monitored for
tumor formation.
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Table 3-1: Tumor promoters upregulated in IgTrkB NCM-1 cells
IgTrkB and WT NCM-1 cells were grown to confluence in 6 well plates and RNA was
isolated using TRI Reagent. Gene expression was determined using a Cancer Pathway
qPCR array plate (SABiosciences). Mycn expression (in bold) was determined
separately by Taqman-based qPCR (ABI). Data is the average of n=3 RNA samples
from 3 different wells of a 6 well plate for each cell line. p-value determined by
Student’s t-test.
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Symbol

Gene

Fold
Regulation

P-value

Description

ccnd1

Cyclin D1

436.1

0.000069

Promotes cell cycle
progression

twist1

Twist homolog 1
(Drosophila)

38.57

0.000015

Promotes epithelialmesenchymal
transition (EMT),
invasion, and
metastasis

hgf

Hepatocyte
growth factor

28.86

0.008818

Promotes mitogenesis,
cell motility, and
matrix invasion

ccnd2

Cyclin D2

26.40

0.000137

Promotes cell cycle
progression

mycn

N-Myc

21.00

0.010000

Marker of aggressive
neuroblastoma

fgf2

Fibroblast growth
factor 2

19.88

0.001753

Promotes angiogenesis

angpt1

Angiopoietin 1

12.25

0.003952

Promotes angiogenesis

abcg2

ATP-binding
cassette, subfamily
G (WHITE),
member 2

6.385

0.000792

Mediates multidrug
resistance

muc1

Mucin 1, cell
surface associated

4.884

0.000030

Inhibits p53-mediated
apoptosis, and
promotes EMT through
b-catenin stabilization

vegfa

Vascular
endothelial growth
factor A

4.816

0.000115

Promotes angiogenesis

serpine1

Serpin peptidase
inhibitor, clade E
(nexin,
plasminogen
activator inhibitor
type 1), member 1

4.661

0.000027

Promotes invasion and
metastasis
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Table 3-2: Tumor suppressors downregulated in IgTrkB NCM-1 cells
IgTrkB and WT NCM-1 cells were grown to confluence in 6 well plates and RNA was
isolated using TRI Reagent. Gene expression was determined using a Cancer Pathway
qPCR array plate (SABiosciences). Data is the average of n=3 RNA samples from 3
different wells of a 6 well plate for each cell line. p-value determined by Student’s t-test.

Symbol

Gene

Fold
Regulation

P-value

Description

thbs1

Thrombospondin 1

-2.118

0.000563

Promotes cell
adhesion

pik3r1

Phosphoinositide-3-kinase,
regulatory subunit 1 (alpha)

-1.913

0.000261

Inhibitor of
PI3K signaling

rb1

Retinoblastoma 1

-1.771

0.000464

Inhibits cell
cycle
progression

tgfbr1

Transforming growth factor,
beta receptor 1

-1.755

0.001248

Inhibits cell
growth

pten

Phosphatase and tensin
homolog

-1.710

0.000285

Inhibits cell
proliferation

bad

BCL2-associated agonist of
cell death

-1.572

0.004340

Promotes
apoptosis

cdkn1a

Cyclin-dependent kinase
inhibitor 1A

-1.514

0.000064

Inhibits cell
cycle
progression
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Figure 3-1: Construction of a constitutively active TrkB receptor by removal of the
two immunoglobulin-like ligand binding domains
(a) The 193 amino acid sequence coding for the two Ig-like ligand binding domains
(shown in grey italics) of the 629 amino acid TrkB protein was removed by restriction
digest. (b) The full-length wild type TrkB protein consists of two cysteine-rich domains
(CRD) surrounding a leucine-rich domain (LRD), two immunoglobulin-like domains
(IGD), and the intracellular tyrosine kinase domain (TKD). In the IgTrkB construct the
two Ig-like domains have been removed.
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Figure 3-2: IgTrkB is expressed and is constitutively active
HEK293 cells were stably transfected with either a WT or IgTrkB construct. Cells were
then treated with or without BDNF (100 ng/mL) and protein was isolated. (a) Western
blot for TrkB and phosphorylated Erk 1/2 demonstrates that IgTrkB is expressed, and
signals in the absence of the TrkB ligand BDNF. (b) Quantification of phosphorylated
Erk 1/2 protein expression reveals a significant increase in phospho Erk 1/2 in IgTrkB
transfected cells treated with (black bars), or without (white bars) BDNF, compared to
untreated WT TrkB transfected cells (p < 0.0001, ANOVA, n=3, error bars = SEM) or
untransfected HEK293 cells. Constitutive IgTrkB activity is two-fifths that of the WT
TrkB receptor treated with BDNF.
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Figure 3-3: IgTrkB promotes process outgrowth in PC12 cells
Transfected cells were assessed for process outgrowth 6 days following transfection. (a)
PC12 cells transfected with GFP have minimal neurite outgrowth, (b) while IgTrkB
transfection stimulates neurite outgrowth. (c) Quantification of process outgrowth in
PC12 cells reveals a 6-fold increase in the number of cells bearing neurites when
transfected with IgTrkB as opposed to a GFP control plasmid (p < 0.0001, Student’s ttest, n=3, error bars = SEM). (d) In the presence of NGF the number of cells bearing
neurites is equivalent in the two transfection conditions. Scale bar is equivalent to 25 m
and applies to both images.

118

Figure 3-4: IgTrkB promotes proliferation in the neural crest derived cell line
NCM-1
(a-f) Phase contrast images of IgTrkB and WT NCM-1 cell growth in a 12-well plate.
Times indicated are hours after plating, 100,000 cells plated at time 0. (g) Calcein AM
uptake reveals a highly significant increase (p < 0.0001, ANOVA) in growth in IgTrkB
NCM-1 cells (closed triangles, points represent mean calcein AM fluorescence, n=16,
error bars = SEM) compared with wild type cells (closed squares) over a 4 day period.
(h-i) IgTrkB NCM-1 cells also have a two-fold increase in expression of the
proliferation marker phosphorylated histone H3 (p < 0.05, Student’s t-test, n=3, error bars
= SEM). (j) The pan-Trk inhibitor K252a (50 nM) abolishes increased proliferation (p <
0.0001, ANOVA, n=8, error bars = SEM) in IgTrkB NCM-1 cells (open triangles)
compared with DMSO treated IgTrkB NCM-1 cells (closed triangles). IgTrkB
proliferation in the presence of K252a is similar to WT NCM-1 proliferation in the
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presence of either K252a (open squares) or DMSO (closed squares). Scale bar is
equivalent to 100 m and applies to all images.

Figure 3-5: IgTrkB promotes anchorage-independent cell growth and anoikis
resistance in NCM-1 cells
Soft agar assay in 6-well plates. (a) Wild type NCM-1 cells have little ability to grow in
soft agar, (b) while IgTrkB NCM-1 cells form numerous colonies. (c) Quantification of
colony growth shows a 25-fold increase in colony formation in IgTrkB NCM-1 cells (p
< 0.001, Student’s t-test, n=6, error bars = SEM). (d) IgTrkB NCM-1 cells are also
resistant to detachment-induced apoptosis marked by a significant increase (p < 0.05,
Student’s t-test, n=4, error bars = SEM) in the number of live cells in suspension as
determined by trypan blue exclusion from media taken from confluent cultures.
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Figure 3-6: IgTrkB enhances migration and invasion of NCM-1 cells
(a-d) Migration of wild type NCM-1 and (e-h) IgTrkB NCM-1 cells. (i) Quantification
of migration shows a significant increase in the area migrated (p < 0.0001, Student’s ttest, n=8, error bars = SEM) in IgTrkB NCM-1 cells (h compared to d), (j) but no
difference in the total number of cells migrated. For invasion assay, cells were overlayed
with matrigel. (k-n) Matrigel invasion in wild type NCM-1 and (o-r) IgTrkB NCM-1
cells. (s) IgTrkB significantly enhances both area invaded (r compared to n), and (t)
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the total number of invading NCM-1 cells (p < 0.05, Student’s t-test, n=3, error bars =
SEM). Scale bar is equivalent to 1 mm and applies to all images.

Figure 3-7: c-Met inhibition abolishes IgTrkB -mediated proliferation in NCM-1
cells
IgTrkB and WT NCM-1 cell proliferation was quantified over a 4 day time period by
calcein AM uptake. Treatment with the c-Met inhibitor SU11274 (1 mM) abolishes
increased proliferation (p < 0.0001, ANOVA, n=8, error bars = SEM) in IgTrkB NCM1 cells (open triangles) compared with DMSO vehicle control treated IgTrkB NCM-1
cells (closed triangles). IgTrkB proliferation in the presence of the c-Met inhibitor is
equal to WT NCM-1 proliferation in the presence of either inhibitor (open squares) or
DMSO (closed squares).
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Figure 3-8: IgTrkB NCM-1 cells form highly aggressive tumors in vivo
(a) Kaplan-Meier plot of tumor-free survival in NOD-SCID mice subcutaneously injected
with WT NCM-1 cells (solid line), or IgTrkB NCM-1 cells (dotted line). No mice
injected with WT NCM-1 cells formed tumors over the course of the experiment (p <
0.01, log-rank (Mantel-Cox) test, n=4). (b) Kaplan-Meier plot of overall survival. All
IgTrkB NCM-1 cell-injected mice had to be sacrificed by 15 days after initial cell
injection due to tumor burden (p < 0.01, log-rank (Mantel-Cox) test, n=4). (c) Estimated
tumor volume over the course of the experiment. IgTrkB NCM-1 cell injected mice
formed rapidly growing tumors starting at 1 week following initial cell injection, with a
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significant difference in tumor volume versus matrigel plug volume by 11 days (p <
0.0001, ANOVA, n=4, error bars = SEM). Removed tumors had an average wet weight
of 4.5 grams. (d) Hematoxylin and Eosin staining of tumor tissue reveals densely packed
cells with scant cytoplasm and absent extracellular stroma reminiscent of poor prognosis
neuroblastoma. (e) Example of mouse injected with WT NCM-1 cells, and (f) IgTrkB
NCM-1 cells (matrigel (e) and tumor (f) are outlined in black). (g-h) In one mouse, the
tumor invaded the spinal cord causing bilateral hind limb paralysis. (g) Normal thoracic
spinal cord (labeled SC) surrounded by vertebrae, rostral to tumor invasion. (h) The
lower thoracic spinal cord (labeled SC) is compressed in the vertebrae by invading tumor
cells (labeled T). Scale bar in (g) is equivalent to 1 mm and also applies to (h). Scale bar
in (d) is equivalent to 100 mm.
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Figure 3-S1: The pBAC-ΔIgTrkB-dsRED construct
The ΔIgTrkB gene was cloned into the first multiple cloning site (MCS) of a bicistronic
construct driven by the CMV-IE Enhancer, chicken β-actin promoter and β-globin intron
(CAG) promoter that was previously inserted into the recombineering region of an
Invitrogen pENTR1a vector. The second MCS of the bicistronic construct after the
IRES2 sequence contained a dsRed Express2 gene. Due to restriction enzyme site limits
the thymidine kinase promoter driven hygromycin gene and polyA was placed in reverse
orientation between the end of the dsRed Express2 gene and its SV40 polyA site. The
pENTR1a vector containing the above described bicistronic construct architecture was
subsequently inserted into a pmhyGENIE-3 plasmid containing a hyperactive piggyBac
gene, by Gateway recombineering as described previously (Urschitz et al., 2010). The
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pmGENIE-3 plasmid containing a mammalian selection cassette expressing an EGFP
gene was constructed as described previously (Urschitz et al., 2010).

Figure 3-S2: IgTrkB is constitutively active in NCM-1 cells
The IgTrkB construct was cloned into a piggyBAC transposon-transposase vector.
NCM-1 cells were then stably transfected with this construct by hygromycin selection.
IgTrkB is constituitively active in the piggyBAC vector (p < 0.01, Student’s t-test, n=3,
error bars = SEM).

Figure 3-S3: Proliferation in NCM-1 cell lines
IgTrkB and WT NCM-1 cells, plus 5 additional NCM-1 cell lines stably transfected
with IgTrkB were grown in culture. All IgTrkB transfected cell lines have enhanced
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proliferation shown by enhanced Calcein AM fluorescence compared to wild type cells
after 4 days in vitro (p < 0.01, ANOVA, n=8, error bars = SEM).

Figure 3-S4: Cyclin D1 protein is upregulated in IgTrkB NCM-1 cells
(a) Western blot of cyclin D1 protein in IgTrkB NCM-1 cells and wild type NCM-1
cells. (b) Quantification of cyclin D1 protein expression reveals a significant 6-fold
upregulation of cyclin D1 protein in IgTrkB NCM-1 cells (p < 0.01, Student’s t-test,
n=3, error bars = SEM).
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS

The experiments presented in this dissertation have aimed to better understand
some of the factors that influence the phenotype of biologically unfavorable
neuroblastoma. We identified ciliary neurotrophic factor signaling to promote
differentiation in MYCN amplified tumors, as well as implicated TrkB signaling as
possibly being sufficient to give rise to neuroblastoma from developing neural crest
precursors. We found that the efficacy of CNTF as an in vivo treatment to reduce growth
of MYCN amplified NHO1S subcutaneous tumors was limited. Due to concerns of
weight loss resulting from intraperitoneal CNTF treatment, animals received only one
week of CNTF treatment. Follow-up studies administering CNTF treatment every other
day, and following tumor growth for up to two weeks may result in a more significant
effect on NHO1S tumor growth. Additionally, the use of the newly engineered TATCNTF fusion protein (Rezende et al., 2009), which does not have the anorexic side
effects of CNTF, would allow for greater flexibility in dosing schedules, assuming that
this fusion protein would have similar differentiating effects in vitro.

We reported that TrkB signaling is sufficient to transform the neural crest
derived cell line NCM-1, suggesting that abberrant TrkB signaling alone may be
sufficient to initiate tumor formation in neuroblastoma. To formally confirm this
hypothesis, the development of a transgenic mouse will be necessary. Using the IgTrkB
construct presented in this dissertation, a transgenic mouse expressing this construct
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targeted to the neural crest lineage by the tyrosine hyrdoxylase (TH) promoter, as in the
TH-MYCN mouse, would help to determine if TrkB signaling can be a driver of
neuroblatoma tumor formation. Furthermore, the utilization of an inducible promoter,
such as an rtTA / TRE tet-On system, would allow the determination of a critical period
for tumorigenesis, or whether or not tumor formation at different points in development
results in different tumor cell phenotypes.

TrkB and ALK – Different Means to the Same End?
It was recently discovered that mutations in ALK, a gene coding for another tyrosine
kinase receptor, were found to be present in the majority of familial cases of
neuroblastoma (Mosse et al., 2008), as well as 5-15% of sporadic cases (Chen et al.,
2008). Like TrkB, gain of function ALK mutations signal through the MAPK and AKT
pathways. In these ALK expressing tumors, constitutively active ALK forms a complex
with hyperphosphorylated ShcC, rendering cells unresponsive to MAPK activating
growth factors such as NGF (Miyake et al., 2002). Furthermore, inhibition of ALK
binding to ShcC results in apoptosis in mutant ALK expressing neuroblastoma cells
(Osajima-Hakomori et al., 2005). Like ALK, TrkB also binds ShcC (Liu and Meakin,
2002). Interestingly, mutations rendering ALK consitutively active are not necessary for
the protein to have oncogenic activity in neuroblastoma. Overexpression of the wild type
(WT) receptor to a critical threshold level leads to constitutive phosphorylation /
activation irrespective of whether cells harbor the mutated or WT receptor (Passoni et al.,
2009). Furthermore, primary tumors with elevated WT ALK expression have similar
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clinical and molecular phenotypes as tumors with activating point mutations (Schulte et
al., 2011).

Is it possible that the oncogenic properties of ALK and TrkB are mediated by the same
mechanism? Both of these tyrosine kinases require high levels of activation of their
receptors, either by overexpression / activating mutations (ALK), or simultaneous
expression of receptor and ligand (TrkB). Furthermore, these receptors activate the same
downstream intracellular pathways in neuroblastoma, utilizing the same ShcC adapter
protein. It would be interesting to determine if disruption of TrkB binding to ShcC would
promote apoptosis in TrkB / BDNF-expressing neuroblastoma cells, as in tumor cells
with elevated ALK activation. If so, this might provide a common therapeutic target for
biologically unfavorable tumor cells harboring these derangements. Alternatively, both
ALK and TrkB signaling converge on the mammalian target of rapamycin (mTOR)
pathway, and mTOR inhibition might reduce the malignant phenotype of both TrkB
(Nakamura et al., 2006) and ALK (Berry et al., 2012) expressing neuroblasotma cells.
Therefore, the further development of mTOR inhibitors as therapeutics in neuroblastoma
will likely have broad efficacy across tumors expressing either TrkB, and mutated or
elevated levels of ALK. The mTOR inhibitor temsirolimus is currently in phase II
clinical trials for refractory neuroblastoma (Geoerger et al., 2012).

CNTF and TrkB Signaling as Personalized Medicine?
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Ultimately, the experiments presented here will not be applicable to all patients with
neuroblastoma. However, as the ability and ease of detection of molecular markers and
genomic signatures is ever increasing, cancer treatments are becoming more and more
personalized to individual patients (Awada et al., 2012). Therefore, in patients who have
failed conventional treatments, yet express the CNTFRa receptor in their tumors,
activation of this signaling pathway might be a legitimate alternative therapeutic option to
promote the differentiation of tumor cells.

Furthermore, the sufficiency of TrkB signaling alone to transform neural crestderived cells strengthens the argument for targeted therapies designed to inhibit TrkB
signaling in TrkB / BDNF-expressing neuroblastomas. Lestaurtinib (CEP-701) is a
tyrosine kinase inhibitor that has shown potential efficacy in phase I clinical trials for
neuroblastoma . Lestaurtinib inhibits Trk activation by ligand at nanomolar
concentrations, and preclinical studies suggest it may be most effective in combination
with conventional chemotherapeutic agents where it renders cells more susceptible to
cytotoxic drugs (Evans, Kisselbach et al. 2001; Ho, Eggert et al. 2002). Encouragingly,
dose-limiting toxicities from Lestaurtinib treatment seem to be limited to nausea,
gastrointestinal irritation, and dyspepsia, which are fairly well tolerated (Marshall,
Kindler et al. 2005). It will be interesting to monitor the progress of this drug through
clinical trials, as therapies specifically targeting the derangements of high risk
neuroblastoma will be necessary to improve upon the current 40% overall survival in the
patient population.

131

References
Awada A, Vandone AM, Aftimos P (2012) Personalized management of patients with
solid cancers: moving from patient characteristics to tumor biology. Curr Opin
Oncol 24:297-304.
Berry T et al. (2012) The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of
MYCN in Neuroblastoma. Cancer Cell 22:117-130.
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A,
Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S (2008) Oncogenic
mutations of ALK kinase in neuroblastoma. Nature 455:971-974.
Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C,
Brodeur GM (2001) Effect of CEP-751 (KT-6587) on neuroblastoma xenografts
expressing TrkB. Med Pediatr Oncol 36:181-184.
Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, Ananthakrishnan
R, Boni JP, Berkenblit A, Spunt SL (2012) Phase II trial of temsirolimus in
children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J
Cancer 48:253-262.
Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE,
Brodeur GM (2002) Resistance to chemotherapy mediated by TrkB in
neuroblastomas. Cancer Res 62:6462-6466.

132

Liu HY, Meakin SO (2002) ShcB and ShcC activation by the Trk family of receptor
tyrosine kinases. J Biol Chem 277:26046-26056.
Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T,
Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ (2005) Phase I trial of
orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine
kinase inhibitor. Invest New Drugs 23:31-37.
Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S,
Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM (2011)
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new
approaches to neuroblastoma therapy consortium study. Cancer Chemother
Pharmacol 68:1057-1065.
Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R (2002)
Activation of anaplastic lymphoma kinase is responsible for
hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21:58235834.
Mosse YP et al. (2008) Identification of ALK as a major familial neuroblastoma
predisposition gene. Nature 455:930-935.
Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ (2006) Brainderived neurotrophic factor activation of TrkB induces vascular endothelial
growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma
cells. Cancer Res 66:4249-4255.

133

Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R (2005)
Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol
167:213-222.
Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C,
Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, GambacortiPasserini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R (2009)
Mutation-independent anaplastic lymphoma kinase overexpression in poor
prognosis neuroblastoma patients. Cancer Res 69:7338-7346.
Rezende AC, Peroni D, Vieira AS, Rogerio F, Talaisys RL, Costa FT, Langone F, Skaper
SD, Negro A (2009) Ciliary neurotrophic factor fused to a protein transduction
domain retains full neuroprotective activity in the absence of cytokine-like side
effects. J Neurochem 109:1680-1690.
Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthur A, Ackermann S,
Kahlert Y, Pajtler K, Theissen J, Westermann F, Vandesompele J, Speleman F,
Berthold F, Eggert A, Brors B, Hero B, Schramm A, Fischer M (2011) High ALK
receptor tyrosine kinase expression supersedes ALK mutation as a determining
factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res
17:5082-5092.

134

COMPREHENSIVE BIBLIOGRAPHY
Anderson DJ, Carnahan JF, Michelsohn A, Patterson PH (1991) Antibody markers
identify a common progenitor to sympathetic neurons and chromaffin cells in
vivo and reveal the timing of commitment to neuronal differentiation in the
sympathoadrenal lineage. J Neurosci 11:3507-3519.
Arakawa Y, Sendtner M, Thoenen H (1990) Survival effect of ciliary neurotrophic factor
(CNTF) on chick embryonic motoneurons in culture: comparison with other
neurotrophic factors and cytokines. J Neurosci 10:3507-3515.
Awada A, Vandone AM, Aftimos P (2012) Personalized management of patients with
solid cancers: moving from patient characteristics to tumor biology. Curr Opin
Oncol 24:297-304.
Baj G, Tongiorgi E (2009) BDNF splice variants from the second promoter cluster
support cell survival of differentiated neuroblastoma upon cytotoxic stress.
Journal of cell science 122:36-43.
Baroffio A, Dupin E, Le Douarin NM (1988) Clone-forming ability and differentiation
potential of migratory neural crest cells. Proceedings of the National Academy of
Sciences of the United States of America 85:5325-5329.
Berry T et al. (2012) The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of
MYCN in Neuroblastoma. Cancer Cell 22:117-130.
Bertrand N, Castro DS, Guillemot F (2002) Proneural genes and the specification of
neural cell types. Nat Rev Neurosci 3:517-530.

135

Birren SJ, Lo L, Anderson DJ (1993) Sympathetic neuroblasts undergo a developmental
switch in trophic dependence. Development 119:597-610.
Black IB, Hendry IA, Iversen LL (1972) The role of post-synaptic neurones in the
biochemical maturation of presynaptic cholinergic nerve terminals in a mouse
sympathetic ganglion. The Journal of physiology 221:149-159.
Bogenmann E, Peterson S, Maekawa K, Matsushima H (1998) Regulation of NGF
responsiveness in human neuroblastoma. Oncogene 17:2367-2376.
Bongioanni P, Reali C, Sogos V (2004) Ciliary neurotrophic factor (CNTF) for
amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst
Rev:CD004302.
Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M (1998) Prognostic
significance of MYCN oncogene expression in childhood neuroblastoma. J Clin
Oncol 16:3286-3294.
Bosse KR et al. (2011) Common variation at BARD1 results in the expression of an
oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
Cancer Res 72:2068-2078.
Botchkarev VA, Botchkareva NV, Lommatzsch M, Peters EM, Lewin GR, Subramaniam
A, Braun A, Renz H, Paus R (1998) BDNF overexpression induces differential
increases among subsets of sympathetic innervation in murine back skin. The
European journal of neuroscience 10:3276-3283.

136

Bourdeaut F, Trochet D, Janoueix-Lerosey I, Ribeiro A, Deville A, Coz C, Michiels JF,
Lyonnet S, Amiel J, Delattre O (2005) Germline mutations of the paired-like
homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett 228:51-58.
Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev
Cancer 3:203-216.
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of
N-myc in untreated human neuroblastomas correlates with advanced disease
stage. Science 224:1121-1124.
Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS (1997a) Biology and
genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93-101.
Brodeur GM, Seeger RC, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D (1986)
Clinical implications of oncogene activation in human neuroblastomas. Cancer
58:541-545.
Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP,
Evans AE (1997b) Expression of TrkA, TrkB and TrkC in human
neuroblastomas. J Neurooncol 31:49-55.
Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V,
Evans AE (2009) Trk receptor expression and inhibition in neuroblastomas. Clin
Cancer Res 15:3244-3250.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi
B, Evans AE, Favrot M, Hedborg F, et al. (1993) Revisions of the international

137

criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin
Oncol 11:1466-1477.
Capasso M et al. (2009) Common variations in BARD1 influence susceptibility to highrisk neuroblastoma. Nat Genet 41:718-723.
Castleberry RP et al. (1997) The International Neuroblastoma Risk Groups (INRG): a
preliminary report. Eur J Cancer 33:2113-2116.
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A,
Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S (2008) Oncogenic
mutations of ALK kinase in neuroblastoma. Nature 455:971-974.
Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson
MS, Hackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M
(2007) Cell lines from MYCN transgenic murine tumours reflect the molecular
and biological characteristics of human neuroblastoma. Eur J Cancer 43:14671475.
Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett
C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J,
Weiss WA (2007) Malignant progression and blockade of angiogenesis in a
murine transgenic model of neuroblastoma. Cancer Res 67:9435-9442.
Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, Eggert A, Schramm
A (2009) Galectin-1 is a major effector of TrkB-mediated neuroblastoma
aggressiveness. Oncogene 28:2015-2023.

138

Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, Thiele CJ (1995)
Induction of transforming growth factor beta 1 and its receptors during all-transretinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines.
Cancer Res 55:2380-2386.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A,
Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V,
Matthay KK (2009) The International Neuroblastoma Risk Group (INRG)
classification system: an INRG Task Force report. J Clin Oncol 27:289-297.
D'Angio GJ, Evans AE, Koop CE (1971) Special pattern of widespread neuroblastoma
with a favourable prognosis. Lancet 1:1046-1049.
De Bernardi B, Balwierz W, Bejent J, Cohn SL, Garre ML, Iehara T, Plantaz D, Simon T,
Angelini P, Cama A, London WB, Kramer K, Katzenstein HM, Tortori-Donati P,
Rossi A, D'Angio GJ, Evans AE (2005) Epidural compression in neuroblastoma:
Diagnostic and therapeutic aspects. Cancer Lett 228:283-299.
De Bernardi B, Pianca C, Pistamiglio P, Veneselli E, Viscardi E, Pession A, Alvisi P,
Carli M, Donfrancesco A, Casale F, Giuliano MG, di Montezemolo LC, Di
Cataldo A, Lo Curto M, Bagnulo S, Schumacher RF, Tamburini A, Garaventa A,
Clemente L, Bruzzi P (2001) Neuroblastoma with symptomatic spinal cord
compression at diagnosis: treatment and results with 76 cases. J Clin Oncol
19:183-190.
De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L,
Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP,

139

Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo
P, Bruzzi P (2003) Disseminated neuroblastoma in children older than one year at
diagnosis: comparable results with three consecutive high-dose protocols adopted
by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21:15921601.
DiCicco-Bloom E, Friedman WJ, Black IB (1993) NT-3 stimulates sympathetic
neuroblast proliferation by promoting precursor survival. Neuron 11:1101-1111.
Dixon JE, McKinnon D (1994) Expression of the trk gene family of neurotrophin
receptors in prevertebral sympathetic ganglia. Brain research 77:177-182.
Doering LC, Roder JC, Henderson JT (1995) Ciliary neurotrophic factor promotes the
terminal differentiation of v-myc immortalized sympathoadrenal progenitor cells
in vivo. Brain Res Dev Brain Res 89:56-66.
Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS (2004)
Suppression of anoikis and induction of metastasis by the neurotrophic receptor
TrkB. Nature 430:1034-1039.
Dupin E, Baroffio A, Dulac C, Cameron-Curry P, Le Douarin NM (1990) Schwann-cell
differentiation in clonal cultures of the neural crest, as evidenced by the antiSchwann cell myelin protein monoclonal antibody. Proceedings of the National
Academy of Sciences of the United States of America 87:1119-1123.
Easton J, Wei T, Lahti JM, Kidd VJ (1998) Disruption of the cyclin D/cyclin-dependent
kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Cancer Res 58:2624-2632.

140

Eckenstein FP, Esch F, Holbert T, Blacher RW, Nishi R (1990) Purification and
characterization of a trophic factor for embryonic peripheral neurons: comparison
with fibroblast growth factors. Neuron 4:623-631.
Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM (2002) Expression of
the neurotrophin receptor TrkA down-regulates expression and function of
angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 62:18021808.
Emsley JG, Hagg T (2003) Endogenous and exogenous ciliary neurotrophic factor
enhances forebrain neurogenesis in adult mice. Exp Neurol 183:298-310.
Ernfors P, Merlio JP, Persson H (1992) Cells Expressing mRNA for Neurotrophins and
their Receptors During Embryonic Rat Development. The European journal of
neuroscience 4:1140-1158.
Ernfors P, Lee KF, Jaenisch R (1994) Mice lacking brain-derived neurotrophic factor
develop with sensory deficits. Nature 368:147-150.
Ernsberger U, Sendtner M, Rohrer H (1989) Proliferation and differentiation of
embryonic chick sympathetic neurons: effects of ciliary neurotrophic factor.
Neuron 2:1275-1284.
Ernsberger U, Patzke H, Rohrer H (1997) The developmental expression of choline
acetyltransferase (ChAT) and the neuropeptide VIP in chick sympathetic neurons:
evidence for different regulatory events in cholinergic differentiation. Mech Dev
68:115-126.

141

Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB,
Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP
(2003) Recombinant variant of ciliary neurotrophic factor for weight loss in obese
adults: a randomized, dose-ranging study. JAMA 289:1826-1832.
Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C,
Brodeur GM (2001) Effect of CEP-751 (KT-6587) on neuroblastoma xenografts
expressing TrkB. Med Pediatr Oncol 36:181-184.
Fagan AM, Zhang H, Landis S, Smeyne RJ, Silos-Santiago I, Barbacid M (1996) TrkA,
but not TrkC, receptors are essential for survival of sympathetic neurons in vivo. J
Neurosci 16:6208-6218.
Feldman JP, Goldwasser R, Mark S, Schwartz J, Orion I (2009) A mathematical model
for tumor volume evaluation using two dimensions. Journal of Applied
Quantitative Methods 4:455-462.
Feng X, Jiang H, Baik JC, Edgar C, Eide FF (2001) BDNF dependence in neuroblastoma.
Journal of neuroscience research 64:355-363.
Francis N, Farinas I, Brennan C, Rivas-Plata K, Backus C, Reichardt L, Landis S (1999)
NT-3, like NGF, is required for survival of sympathetic neurons, but not their
precursors. Dev Biol 210:411-427.
Friedman GK, Castleberry RP (2007) Changing trends of research and treatment in infant
neuroblastoma. Pediatric blood & cancer 49:1060-1065.

142

Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS (1995) Hepatocyte growth
factor and Met receptor expression in human pancreatic carcinogenesis. Am J
Pathol 147:889-895.
Garcia-Suarez O, Naves FJ, Del Valle ME, Esteban I, Bronzetti E, Vazquez E, Vega JA
(1996) Distribution of p75 and trk-neurotrophin receptor proteins in adult human
sympathetic ganglia. Anat Embryol (Berl) 193:577-583.
Geiger TR, Peeper DS (2007) Critical role for TrkB kinase function in anoikis
suppression, tumorigenesis, and metastasis. Cancer Res 67:6221-6229.
George RE et al. (2008) Activating mutations in ALK provide a therapeutic target in
neuroblastoma. Nature 455:975-978.
Gestblom C, Grynfeld A, Ora I, Ortoft E, Larsson C, Axelson H, Sandstedt B, Cserjesi P,
Olson EN, Pahlman S (1999) The basic helix-loop-helix transcription factor
dHAND, a marker gene for the developing human sympathetic nervous system, is
expressed in both high- and low-stage neuroblastomas. Lab Invest 79:67-79.
Glass DJ, Nye SH, Hantzopoulos P, Macchi MJ, Squinto SP, Goldfarb M, Yancopoulos
GD (1991) TrkB mediates BDNF/NT-3-dependent survival and proliferation in
fibroblasts lacking the low affinity NGF receptor. Cell 66:405-413.
Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL (1997) Infant
cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J
Pediatr Hematol Oncol 19:428-432.

143

Haapasalo A, Koponen E, Hoppe E, Wong G, Castren E (2001) Truncated trkB.T1 is
dominant negative inhibitor of trkB.TK+-mediated cell survival. Biochemical and
biophysical research communications 280:1352-1358.
Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ,
Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA (2003) Genomewide array CGH analysis of murine neuroblastoma reveals distinct genomic
aberrations which parallel those in human tumors. Cancer Res 63:5266-5273.
Hagg T, Quon D, Higaki J, Varon S (1992) Ciliary neurotrophic factor prevents neuronal
degeneration and promotes low affinity NGF receptor expression in the adult rat
CNS. Neuron 8:145-158.
Halvorsen SW, Malek R, Wang X, Jiang N (1996) Ciliary neurotrophic factor regulates
nicotinic acetylcholine receptors on human neuroblastoma cells.
Neuropharmacology 35:257-265.
Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, Haber
M, Armati PJ, Weiss WA, Marshall GM (2004) Mechanisms of embryonal tumor
initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl
Acad Sci U S A 101:12664-12669.
Haraguchi S, Nakagawara A (2009) A simple PCR method for rapid genotype analysis of
the TH-MYCN transgenic mouse. PLoS One 4:e6902.
Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L (2005) The neurotrophin
receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness.
Carcinogenesis 26:2105-2115.

144

Heller S, Ernsberger U, Rohrer H (1996) Extrinsic signals in the developing nervous
system: the role of neurokines during neurogenesis. Perspect Dev Neurobiol 4:1934.
Henderson JT, Seniuk NA, Richardson PM, Gauldie J, Roder JC (1994) Systemic
administration of ciliary neurotrophic factor induces cachexia in rodents. J Clin
Invest 93:2632-2638.
Hirsch MR, Tiveron MC, Guillemot F, Brunet JF, Goridis C (1998) Control of
noradrenergic differentiation and Phox2a expression by MASH1 in the central
and peripheral nervous system. Development 125:599-608.
Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE,
Brodeur GM (2002) Resistance to chemotherapy mediated by TrkB in
neuroblastomas. Cancer Res 62:6462-6466.
Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur
GM (2005) Proliferation of human neuroblastomas mediated by the epidermal
growth factor receptor. Cancer Res 65:9868-9875.
Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S (1996) A
developmental model of neuroblastoma: differentiating stroma-poor tumors'
progress along an extra-adrenal chromaffin lineage. Lab Invest 75:659-675.
Howard MJ, Stanke M, Schneider C, Wu X, Rohrer H (2000) The transcription factor
dHAND is a downstream effector of BMPs in sympathetic neuron specification.
Development 127:4073-4081.

145

Hruska M, Nishi R (2007) Cell-autonomous inhibition of alpha 7-containing nicotinic
acetylcholine receptors prevents death of parasympathetic neurons during
development. J Neurosci 27:11501-11509.
Huang YT, Lai PC, Wu CC, Hsu SH, Cheng CC, Lan YF, Chiu TH (2010) BDNF
mediated TrkB activation is a survival signal for transitional cell carcinoma cells.
Int J Oncol 36:1469-1476.
Huber K (2006) The sympathoadrenal cell lineage: specification, diversification, and new
perspectives. Dev Biol 298:335-343.
Ichimiya S, Nimura Y, Seki N, Ozaki T, Nagase T, Nakagawara A (2001)
Downregulation of hASH1 is associated with the retinoic acid-induced
differentiation of human neuroblastoma cell lines. Medical and pediatric oncology
36:132-134.
Ip NY, Li YP, van de Stadt I, Panayotatos N, Alderson RF, Lindsay RM (1991) Ciliary
neurotrophic factor enhances neuronal survival in embryonic rat hippocampal
cultures. J Neurosci 11:3124-3134.
Ip NY, McClain J, Barrezueta NX, Aldrich TH, Pan L, Li Y, Wiegand SJ, Friedman B,
Davis S, Yancopoulos GD (1993) The alpha component of the CNTF receptor is
required for signaling and defines potential CNTF targets in the adult and during
development. Neuron 10:89-102.
Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B,
Yamamoto T (1997) Molecular characterization of ALK, a receptor tyrosine
kinase expressed specifically in the nervous system. Oncogene 14:439-449.

146

Jaboin J, Kim CJ, Kaplan DR, Thiele CJ (2002) Brain-derived neurotrophic factor
activation of TrkB protects neuroblastoma cells from chemotherapy-induced
apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res 62:6756-6763.
Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V,
Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D,
Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O (2008) Somatic and
germline activating mutations of the ALK kinase receptor in neuroblastoma.
Nature 455:967-970.
Kaneko Y, Kanda N, Maseki N, Sakurai M, Tsuchida Y, Takeda T, Okabe I (1987)
Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer
Res 47:311-318.
Kao S, Jaiswal RK, Kolch W, Landreth GE (2001) Identification of the mechanisms
regulating the differential activation of the mapk cascade by epidermal growth
factor and nerve growth factor in PC12 cells. The Journal of biological chemistry
276:18169-18177.
Kaplan SJ, Holbrook CT, McDaniel HG, Buntain WL, Crist WM (1980) Vasoactive
intestinal peptide secreting tumors of childhood. Am J Dis Child 134:21-24.
Kessler JA, Black IB (1980) The effects of nerve growth factor (NGF) and antiserum to
NGF on the development of embryonic sympathetic neurons in vivo. Brain Res
189:157-168.

147

Kim CJ, Matsuo T, Lee KH, Thiele CJ (1999) Up-regulation of insulin-like growth
factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y
neuroblastoma cells. Am J Pathol 155:1661-1670.
Klein R, Smeyne RJ, Wurst W, Long LK, Auerbach BA, Joyner AL, Barbacid M (1993)
Targeted disruption of the trkB neurotrophin receptor gene results in nervous
system lesions and neonatal death. Cell 75:113-122.
Klein R, Silos-Santiago I, Smeyne RJ, Lira SA, Brambilla R, Bryant S, Zhang L, Snider
WD, Barbacid M (1994) Disruption of the neurotrophin-3 receptor gene trkC
eliminates la muscle afferents and results in abnormal movements. Nature
368:249-251.
Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S, Cordon-Cardo C, Jones
KR, Reichardt LF, Barbacid M (1991) The trkB tyrosine protein kinase is a
receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 66:395403.
Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myc is essential during neurogenesis
for the rapid expansion of progenitor cell populations and the inhibition of
neuronal differentiation. Genes Dev 16:2699-2712.
Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J,
Holsinger FC, Yu D, Myers JN (2010) TrkB induces EMT and has a key role in
invasion of head and neck squamous cell carcinoma. Oncogene 29:2047-2059.
Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL,
Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ (2001) Ciliary

148

neurotrophic factor activates leptin-like pathways and reduces body fat, without
cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad
Sci U S A 98:4652-4657.
Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlman S (1995) Transfection of
TRK-A into human neuroblastoma cells restores their ability to differentiate in
response to nerve growth factor. Cell Growth Differ 6:727-736.
Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter
T, Knudsen B, Vande Woude GF, Harbeck N (2005) C-Met overexpression in
node-positive breast cancer identifies patients with poor clinical outcome
independent of Her2/neu. Int J Cancer 113:678-682.
Levi-Montalcini R, Booker B (1960a) Destruction of the Sympathetic Ganglia in
Mammals by an Antiserum to a Nerve-Growth Protein. Proceedings of the
National Academy of Sciences of the United States of America 46:384-391.
Levi-Montalcini R, Booker B (1960b) Excessive Growth of the Sympathetic Ganglia
Evoked by a Protein Isolated from Mouse Salivary Glands. Proceedings of the
National Academy of Sciences of the United States of America 46:373-384.
Li Z, Tan F, Thiele CJ (2007) Inactivation of glycogen synthase kinase-3beta contributes
to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in
neuroblastoma cells. Molecular cancer therapeutics 6:3113-3121.
Li Z, Jaboin J, Dennis PA, Thiele CJ (2005) Genetic and pharmacologic identification of
Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of

149

neuroblastoma cells from chemotherapy-induced cell death. Cancer research
65:2070-2075.
Lin LF, Mismer D, Lile JD, Armes LG, Butler ET, 3rd, Vannice JL, Collins F (1989)
Purification, cloning, and expression of ciliary neurotrophic factor (CNTF).
Science 246:1023-1025.
Liu C, Park M, Tsao MS (1992) Overexpression of c-met proto-oncogene but not
epidermal growth factor receptor or c-erbB-2 in primary human colorectal
carcinomas. Oncogene 7:181-185.
Liu HY, Meakin SO (2002) ShcB and ShcC activation by the Trk family of receptor
tyrosine kinases. J Biol Chem 277:26046-26056.
Lo L, Sommer L, Anderson DJ (1997) MASH1 maintains competence for BMP2-induced
neuronal differentiation in post-migratory neural crest cells. Curr Biol 7:440-450.
Lo LC, Birren SJ, Anderson DJ (1991) V-myc immortalization of early rat neural crest
cells yields a clonal cell line which generates both glial and adrenergic progenitor
cells. Dev Biol 145:139-153.
London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P,
Brodeur G, Maris JM, Reynolds CP, Cohn SL (2005) Evidence for an age cutoff
greater than 365 days for neuroblastoma risk group stratification in the Children's
Oncology Group. J Clin Oncol 23:6459-6465.
Longo L, Borghini S, Schena F, Parodi S, Albino D, Bachetti T, Da Prato L, Truini M,
Gambini C, Tonini GP, Ceccherini I, Perri P (2008) PHOX2A and PHOX2B

150

genes are highly co-expressed in human neuroblastoma. International journal of
oncology 33:985-991.
Lugo TG, Witte ON (1989) The BCR-ABL oncogene transforms Rat-1 cells and
cooperates with v-myc. Mol Cell Biol 9:1263-1270.
Mahoney NR, Liu GT, Menacker SJ, Wilson MC, Hogarty MD, Maris JM (2006)
Pediatric horner syndrome: etiologies and roles of imaging and urine studies to
detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol
142:651-659.
Mains RE, Patterson PH (1973) Primary cultures of dissociated sympathetic neurons. III.
Changes in metabolism with age in culture. J Cell Biol 59:361-366.
Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol
17:2264-2279.
Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369:21062120.
Maris JM et al. (2008) Chromosome 6p22 locus associated with clinically aggressive
neuroblastoma. N Engl J Med 358:2585-2593.
Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T,
Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ (2005) Phase I trial of
orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine
kinase inhibitor. Invest New Drugs 23:31-37.

151

Martens LK, Kirschner KM, Warnecke C, Scholz H (2007) Hypoxia-inducible factor-1
(HIF-1) is a transcriptional activator of the TrkB neurotrophin receptor gene. The
Journal of biological chemistry 282:14379-14388.
Martin-Zanca D, Hughes SH, Barbacid M (1986) A human oncogene formed by the
fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature
319:743-748.
Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ (1995) Expression of
brain-derived neurotrophic factor and p145TrkB affects survival, differentiation,
and invasiveness of human neuroblastoma cells. Cancer Res 55:1798-1806.
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P,
Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment
of high-risk neuroblastoma with intensive chemotherapy, radiotherapy,
autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's
Cancer Group. N Engl J Med 341:1165-1173.
McKenzie AJ, Campbell SL, Howe AK (2011) Protein kinase A activity and anchoring
are required for ovarian cancer cell migration and invasion. PLoS One 6:e26552.
Miller FD, Kaplan DR (2001) Neurotrophin signalling pathways regulating neuronal
apoptosis. Cell Mol Life Sci 58:1045-1053.
Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, Goodpasture JC
(1996) Toxicity and tolerability of recombinant human ciliary neurotrophic factor
in patients with amyotrophic lateral sclerosis. Neurology 47:1329-1331.

152

Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S,
Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM (2011)
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new
approaches to neuroblastoma therapy consortium study. Cancer Chemother
Pharmacol 68:1057-1065.
Mitchell WG, Davalos-Gonzalez Y, Brumm VL, Aller SK, Burger E, Turkel SB,
Borchert MS, Hollar S, Padilla S (2002) Opsoclonus-ataxia caused by childhood
neuroblastoma: developmental and neurologic sequelae. Pediatrics 109:86-98.
Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM (1994) Arrest
of motor neuron disease in wobbler mice cotreated with CNTF and BDNF.
Science 265:1107-1110.
Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R (2002)
Activation of anaplastic lymphoma kinase is responsible for
hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21:58235834.
Miyamoto Y, Yamauchi J, Tanoue A, Wu C, Mobley WC (2006) TrkB binds and
tyrosine-phosphorylates Tiam1, leading to activation of Rac1 and induction of
changes in cellular morphology. Proceedings of the National Academy of
Sciences of the United States of America 103:10444-10449.
Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN (2003) Rearrangements and
increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes
Chromosomes Cancer 36:242-249.

153

Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D,
Ora I, Speleman F, Caron HN, Versteeg R Copy number defects of G1-cell cycle
genes in neuroblastoma are frequent and correlate with high expression of E2F
target genes and a poor prognosis. Genes Chromosomes Cancer 51:10-19.
Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D,
Ora I, Speleman F, Caron HN, Versteeg R (2011) Copy number defects of G1-cell
cycle genes in neuroblastoma are frequent and correlate with high expression of
E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51:10-19.
Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat
PE, Ponthan F, O'Toole K, Lunec J, Tweddle DA (2008) Histological profile of
tumours from MYCN transgenic mice. J Clin Pathol 61:1098-1103.
Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, Maris JM
(2004) Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum
Genet 75:727-730.
Mosse YP et al. (2008) Identification of ALK as a major familial neuroblastoma
predisposition gene. Nature 455:930-935.
Nakagawara A (1998) Molecular basis of spontaneous regression of neuroblastoma: role
of neurotrophic signals and genetic abnormalities. Hum Cell 11:115-124.
Nakagawara A, Brodeur GM (1997) Role of neurotrophins and their receptors in human
neuroblastomas: a primary culture study. Eur J Cancer 33:2050-2053.
Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of
TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759-767.

154

Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM (1992) Inverse
relationship between trk expression and N-myc amplification in human
neuroblastomas. Cancer Res 52:1364-1368.
Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM
(1993) Association between high levels of expression of the TRK gene and
favorable outcome in human neuroblastoma. N Engl J Med 328:847-854.
Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ (2006) Brainderived neurotrophic factor activation of TrkB induces vascular endothelial
growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma
cells. Cancer Res 66:4249-4255.
Oppenheim RW, Prevette D, Yin QW, Collins F, MacDonald J (1991) Control of
embryonic motoneuron survival in vivo by ciliary neurotrophic factor. Science
251:1616-1618.
Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R (2005)
Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol
167:213-222.
Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C,
Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, GambacortiPasserini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R (2009)
Mutation-independent anaplastic lymphoma kinase overexpression in poor
prognosis neuroblastoma patients. Cancer Res 69:7338-7346.

155

Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL (2005) A neurotrophin axis in
myeloma: TrkB and BDNF promote tumor-cell survival. Blood 105:4429-4436.
Plantaz D, Rubie H, Michon J, Mechinaud F, Coze C, Chastagner P, Frappaz D, Gigaud
M, Passagia JG, Hartmann O (1996) The treatment of neuroblastoma with
intraspinal extension with chemotherapy followed by surgical removal of residual
disease. A prospective study of 42 patients--results of the NBL 90 Study of the
French Society of Pediatric Oncology. Cancer 78:311-319.
Quinn JJ, Altman AJ (1979) The multiple hematologic manifestations of neuroblastoma.
Am J Pediatr Hematol Oncol 1:201-205.
Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL (2000) Overexpression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF
receptor (cMET) are associated with a high risk of metastasis and recurrence for
children and young adults with papillary thyroid carcinoma. Clin Endocrinol
(Oxf) 53:635-644.
Ramsay GM, Moscovici G, Moscovici C, Bishop JM (1990) Neoplastic transformation
and tumorigenesis by the human protooncogene MYC. Proc Natl Acad Sci U S A
87:2102-2106.
Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc
Lond B Biol Sci 361:1545-1564.
Reiff T, Tsarovina K, Majdazari A, Schmidt M, del Pino I, Rohrer H Neuroblastoma
phox2b variants stimulate proliferation and dedifferentiation of immature
sympathetic neurons. J Neurosci 30:905-915.

156

Reiff T, Huber L, Kramer M, Delattre O, Janoueix-Lerosey I, Rohrer H (2011) Midkine
and Alk signaling in sympathetic neuron proliferation and neuroblastoma
predisposition. Development 138:4699-4708.
Rezende AC, Peroni D, Vieira AS, Rogerio F, Talaisys RL, Costa FT, Langone F, Skaper
SD, Negro A (2009) Ciliary neurotrophic factor fused to a protein transduction
domain retains full neuroprotective activity in the absence of cytokine-like side
effects. J Neurochem 109:1680-1690.
Rossino P, Volpe G, Negro A, Callegaro L, Altruda F, Tarone G, Silengo L (1995)
Ciliary neurotrophic factor-induced gene expression in human neuroblastoma cell
lines. Neurochem Res 20:675-680.
Ryden M, Sehgal R, Dominici C, Schilling FH, Ibanez CF, Kogner P (1996) Expression
of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable
tumour stage and good prognosis. Br J Cancer 74:773-779.
Saadat S, Sendtner M, Rohrer H (1989) Ciliary neurotrophic factor induces cholinergic
differentiation of rat sympathetic neurons in culture. J Cell Biol 108:1807-1816.
Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, Mori T, Maeda K, Koide R,
Hanawa Y, Tsunoda A, et al. (1984) Mass screening for neuroblastoma in infants
in Japan. Interim report of a mass screening study group. Lancet 2:271-273.
Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H (1993) Defects of
embryonic organogenesis resulting from targeted disruption of the N-myc gene in
the mouse. Development 117:1445-1455.

157

Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, Spengler BA, Lucarelli E,
Bates SE, Thiele CJ (1996) Brain-derived neurotrophic factor protects
neuroblastoma cells from vinblastine toxicity. Cancer research 56:3737-3742.
Schecterson LC, Bothwell M (1992) Novel roles for neurotrophins are suggested by
BDNF and NT-3 mRNA expression in developing neurons. Neuron 9:449-463.
Schmidt RE, Dorsey DA, Selznick LA, DiStefano PS, Carroll SL, Beaudet LN, Roth KA
(1998) Neurotrophin sensitivity of prevertebral and paravertebral rat sympathetic
autonomic ganglia. Journal of neuropathology and experimental neurology
57:158-167.
Schneider C, Wicht H, Enderich J, Wegner M, Rohrer H (1999) Bone morphogenetic
proteins are required in vivo for the generation of sympathetic neurons. Neuron
24:861-870.
Schober A, Minichiello L, Keller M, Huber K, Layer PG, Roig-Lopez JL, Garcia-Arraras
JE, Klein R, Unsicker K (1997) Reduced acetylcholinesterase (AChE) activity in
adrenal medulla and loss of sympathetic preganglionic neurons in TrkA-deficient,
but not TrkB-deficient, mice. J Neurosci 17:891-903.
Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt V, Sieverts H, KuhfittigKulle S, Pfeiffer P, Versteeg R, Eggert A (2005) Biological effects of TrkA and
TrkB receptor signaling in neuroblastoma. Cancer Lett 228:143-153.
Schulte JH, Schramm A, Klein-Hitpass L, Klenk M, Wessels H, Hauffa BP, Eils J, Eils
R, Brodeur GM, Schweigerer L, Havers W, Eggert A (2005) Microarray analysis
reveals differential gene expression patterns and regulation of single target genes

158

contributing to the opposing phenotype of TrkA- and TrkB-expressing
neuroblastomas. Oncogene 24:165-177.
Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte
S, Molenaar J, Versteeg R, Thor T, Kunkele A, Vandesompele J, Speleman F,
Schorle H, Eggert A, Schramm A (2012) MYCN and ALKF1174L are sufficient
to drive neuroblastoma development from neural crest progenitor cells.
Oncogene.
Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthur A, Ackermann S,
Kahlert Y, Pajtler K, Theissen J, Westermann F, Vandesompele J, Speleman F,
Berthold F, Eggert A, Brors B, Hero B, Schramm A, Fischer M (2011) High ALK
receptor tyrosine kinase expression supersedes ALK mutation as a determining
factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res
17:5082-5092.
Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM (1984) Enhanced
expression of the human gene N-myc consequent to amplification of DNA may
contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A
81:4940-4944.
Screaton RA, Penn LZ, Stanners CP (1997) Carcinoembryonic antigen, a human tumor
marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol
137:939-952.

159

Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D (1985)
Association of multiple copies of the N-myc oncogene with rapid progression of
neuroblastomas. N Engl J Med 313:1111-1116.
Sendtner M, Kreutzberg GW, Thoenen H (1990) Ciliary neurotrophic factor prevents the
degeneration of motor neurons after axotomy. Nature 345:440-441.
Shah NM, Groves AK, Anderson DJ (1996) Alternative neural crest cell fates are
instructively promoted by TGFbeta superfamily members. Cell 85:331-343.
Shimada H, Chatten J, Newton WA, Jr., Sachs N, Hamoudi AB, Chiba T, Marsden HB,
Misugi K (1984) Histopathologic prognostic factors in neuroblastic tumors:
definition of subtypes of ganglioneuroblastoma and an age-linked classification of
neuroblastomas. J Natl Cancer Inst 73:405-416.
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB,
Lukens JN, Matthay KK, Castleberry RP (1999) The International Neuroblastoma
Pathology Classification (the Shimada system). Cancer 86:364-372.
Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugieres L,
Feunteun J, Hartmann O, Bonaiti-Pellie C (2004) Genetic epidemiology of
neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France.
Pediatr Blood Cancer 42:99-105.
Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, Lira SA, Barbacid M
(1994) Severe sensory and sympathetic neuropathies in mice carrying a disrupted
Trk/NGF receptor gene. Nature 368:246-249.

160

Snider WD (1994) Functions of the neurotrophins during nervous system development:
what the knockouts are teaching us. Cell 77:627-638.
Soderholm H, Ortoft E, Johansson I, Ljungberg J, Larsson C, Axelson H, Pahlman S
(1999) Human achaete-scute homologue 1 (HASH-1) is downregulated in
differentiating neuroblastoma cells. Biochemical and biophysical research
communications 256:557-563.
Squinto SP, Aldrich TH, Lindsay RM, Morrissey DM, Panayotatos N, Bianco SM, Furth
ME, Yancopoulos GD (1990) Identification of functional receptors for ciliary
neurotrophic factor on neuronal cell lines and primary neurons. Neuron 5:757766.
Stanke M, Junghans D, Geissen M, Goridis C, Ernsberger U, Rohrer H (1999) The Phox2
homeodomain proteins are sufficient to promote the development of sympathetic
neurons. Development 126:4087-4094.
Straub JA, Sholler GL, Nishi R (2007) Embryonic sympathoblasts transiently express
TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in
vitro. BMC developmental biology 7:10.
Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, Sferra R,
Rucci N, Argenti B, Screpanti I, Gulino A, Mackay AR (2004) TrkA alternative
splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer
Cell 6:347-360.
Tessarollo L, Tsoulfas P, Donovan MJ, Palko ME, Blair-Flynn J, Hempstead BL, Parada
LF (1997) Targeted deletion of all isoforms of the trkC gene suggests the use of

161

alternate receptors by its ligand neurotrophin-3 in neuronal development and
implicates trkC in normal cardiogenesis. Proc Natl Acad Sci U S A 94:1477614781.
Thaler CD, Suhr L, Ip N, Katz DM (1994) Leukemia inhibitory factor and neurotrophins
support overlapping populations of rat nodose sensory neurons in culture. Dev
Biol 161:338-344.
Tlsty TD (1990) Normal diploid human and rodent cells lack a detectable frequency of
gene amplification. Proc Natl Acad Sci U S A 87:3132-3136.
Tokunou M, Niki T, Eguchi K, Iba S, Tsuda H, Yamada T, Matsuno Y, Kondo H, Saitoh
Y, Imamura H, Hirohashi S (2001) c-MET expression in myofibroblasts: role in
autocrine activation and prognostic significance in lung adenocarcinoma. Am J
Pathol 158:1451-1463.
Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G,
Coze C, Philip N, Frebourg T, Munnich A, Lyonnet S, Delattre O, Amiel J (2004)
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in
neuroblastoma. Am J Hum Genet 74:761-764.
Urschitz J, Kawasumi M, Owens J, Morozumi K, Yamashiro H, Stoytchev I, Marh J, Dee
JA, Kawamoto K, Coates CJ, Kaminski JM, Pelczar P, Yanagimachi R, Moisyadi
S Helper-independent piggyBac plasmids for gene delivery approaches: strategies
for avoiding potential genotoxic effects. Proc Natl Acad Sci U S A 107:81178122.

162

Urschitz J, Kawasumi M, Owens J, Morozumi K, Yamashiro H, Stoytchev I, Marh J, Dee
JA, Kawamoto K, Coates CJ, Kaminski JM, Pelczar P, Yanagimachi R, Moisyadi
S (2010) Helper-independent piggyBac plasmids for gene delivery approaches:
strategies for avoiding potential genotoxic effects. Proc Natl Acad Sci U S A
107:8117-8122.
Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V,
Krause A, Leissner P, Puisieux A (2004) Oncogenic cooperation between HTwist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6:625630.
van Limpt V, Schramm A, van Lakeman A, Sluis P, Chan A, van Noesel M, Baas F,
Caron H, Eggert A, Versteeg R (2004) The Phox2B homeobox gene is mutated in
sporadic neuroblastomas. Oncogene 23:9280-9288.
van Noesel MM, Hahlen K, Hakvoort-Cammel FG, Egeler RM (1997) Neuroblastoma
4S: a heterogeneous disease with variable risk factors and treatment strategies.
Cancer 80:834-843.
Varon S, Manthorpe M, Adler R (1979) Cholinergic neuronotrophic factors: I. Survival,
neurite outgrowth and choline acetyltransferase activity in monolayer cultures
from chick embryo ciliary ganglia. Brain Res 173:29-45.
Wang K et al. (2011) Integrative genomics identifies LMO1 as a neuroblastoma
oncogene. Nature 469:216-220.

163

Wartiovaara K, Barnabe-Heider F, Miller FD, Kaplan DR (2002) N-myc promotes
survival and induces S-phase entry of postmitotic sympathetic neurons. J
Neurosci 22:815-824.
Weiss WA, Godfrey T, Francisco C, Bishop JM (2000) Genome-wide screen for allelic
imbalance in a mouse model for neuroblastoma. Cancer Res 60:2483-2487.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted
expression of MYCN causes neuroblastoma in transgenic mice. EMBO J
16:2985-2995.
Wetmore C, Olson L (1995) Neuronal and nonneuronal expression of neurotrophins and
their receptors in sensory and sympathetic ganglia suggest new intercellular
trophic interactions. The Journal of comparative neurology 353:143-159.
Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, Brossard J,
Hill G, Shuster J, Luepker R, Byrne T, Weitzman S, Bunin G, Lemieux B (1996)
A population-based study of the usefulness of screening for neuroblastoma.
Lancet 348:1682-1687.
Wright JA, Smith HS, Watt FM, Hancock MC, Hudson DL, Stark GR (1990) DNA
amplification is rare in normal human cells. Proc Natl Acad Sci U S A 87:17911795.
Yamashiro DJ, Nakagawara A, Ikegaki N, Liu XG, Brodeur GM (1996) Expression of
TrkC in favorable human neuroblastomas. Oncogene 12:37-41.

164

Yamashiro DJ, Liu XG, Lee CP, Nakagawara A, Ikegaki N, McGregor LM, Baylin SB,
Brodeur GM (1997) Expression and function of Trk-C in favourable human
neuroblastomas. Eur J Cancer 33:2054-2057.
Yao R, Cooper GM (1995) Requirement for phosphatidylinositol-3 kinase in the
prevention of apoptosis by nerve growth factor. Science (New York, NY
267:2003-2006.
Yu Y, Zhang S, Wang X, Yang Z, Ou G (2006) Overexpression of TrkB promotes the
progression of colon cancer. APMIS 118:188-195.
Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, Lu Y, Cui Z, Qiu X (2010) TrkB is
highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2
signaling and the invasion of A549 cells. BMC Cancer 10:43.
Zhou H, Welcher AA, Shooter EM (1997) BDNF/NT4-5 receptor TrkB and cadherin
participate in cell-cell adhesion. Journal of neuroscience research 49:281-291.

165

APPENDIX A: Expression of the 5 nicotinic acetylcholine receptor subunit in
neuroblastoma

Despite surgery and chemotherapy, outcomes in high risk neuroblastoma remain
poor (De Bernardi, Nicolas et al. 2003). Many of these patients will initially respond to
chemotherapy, but inevitably relapse. One possibility for these outcomes is the presence
of a cancer stem cell in the bone marrow that, after surviving chemotherapy treatment, is
able to reseed the body and initiate new tumor development. Such ‘tumor initiating cells’
or TICs, have been isolated from the bone marrow of relapsed neuroblastoma patients
(Hansford, McKee et al. 2007). Therefore, in order to prevent relapse in high risk
neuroblastoma, new therapeutics must be developed which target these tumor initiating
cells.

In an effort to identify compounds with the ability to kill TICs, but not normal
cells, the lab of Dr. Kaplan at the Hospital for Sick Children in Toronto, Canada
performed a candidate drug screen (Smith, Datti et al. 2010). This screen identified the
drug MG 624, a nicotinic acetylcholine receptor antagonist, to kill TICs, but not normal
skin-derived neural crest precursor cells (SKPs) (Fig. A-1, unpublished data). Therefore,
we became interested in identifying what nicotinic acetylcholine receptor subunits may
be expressed in neuroblastoma TICs, and whether this subunit expression contributes to
the tumorigenic phenotype of these cells.
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To determine nicotinic acetylcholine receptor (CHRN) subunit expression in
TICs, I isolated total RNA from one TIC line from the lab of Dr. Kaplan (NB12), and
from one TIC line isolated by Dr. Giselle Sholler (BO11SC). RNA was converted to
cDNA and I performed quantitative PCR for the CHRN subunits 3 (CHRNA3), 4
(CHRNA4), 5 (CHRNA5), 7 (CHRNA7), 2 (CHRNB2), and 4 (CHRNB4).
Expression was compared to RNA isolated from a normal pediatric sympathetic ganglion
(Fig. A-2). While CHRNA3, CHRNA4, and CHRNB4 are not expressed in the TIC
lines, interestingly, CHRNA5 is highly upregulated in the TIC lines compared with
normal sympathetic control. CHRNA7 and CHRNB2 are expressed in the TIC lines, but
at relatively low levels compared with control. Therefore, we reasoned CHRNA5
expression may be important in the ability of MG624 to kill TICs.

To determine if the observed upregulation of CHRNA5 would be consistent with other
TIC lines, as well as compared to other controls, such as the normal skin derived neural
crest precursor cells (SKPs) used in the candidate drug screen, Dr. Kaplan and Dr. Miller
generously provided us with RNA isolated from a number of different TIC and SKP
lines. The same quantitative PCR was performed, and consistent with the first TIC lines,
CHRNA5 is highly upregulated in all TIC lines tested (purple bars) compared with both
SKP lines (aqua bars), and the normal sympathetic tissue control (yellow bar) (Figure A3). Furthermore, as in the first TIC lines, CHRNA3, CHRNA4, and CHRNB4 are not
expressed, while CHRNA7 and CHRNB2 are lowly expressed in all TIC lines.
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Next we examined whether upregulation of CHRNA5 was a characteristic specific to
neuroblastoma TICs, or whether CHRNA5 is highly expressed in established
neuroblastoma cell lines as well. RNA was isolated from two MYCN-amplified (KCN
and KCNR) and one single-copy MYCN (SY5Y) neuroblastoma cell lines, and mRNA
transcript levels were determined for CHRNA5 and CHRNA7 by quantitative PCR (Fig.
A-4). As in the TICs, CHRNA5 is highly upregulated in all three neuroblastoma cell
lines tested compared with normal sympathetic control, indicating CHRNA5
overexpression is not exclusive to neuroblastoma tumor initiating cells. CHRNA7 was
also expressed in the neuroblastoma cell lines. However, unlike in the TICs, where
CHRNA7 expression was well below that of the sympathetic control, CHRNA7
expression levels in the neuroblastoma cell lines were equivalent to levels in the
sympathetic control tissue.

We observed upregulation of CHRNA5 in both neuroblastoma tumor initiating cells, and
in established neuroblastoma cell lines. However, both of these groups of cells are grown
in culture, and therefore do not reveal whether or not CHRNA5 is upregulated in vivo.
To determine if CHRNA5 is overexpressed in the tumors of neuroblastoma patients in
vivo, RNA from a number of patient’s tumors was generously provided by the Children
Oncology Group (COG). This RNA was converted to cDNA and CHRNA5 transcript
levels were determined by quantitative PCR as above. Consistent with expression in both
the TICs, and established neuroblastoma cells, CHRNA5 was upregulated in every tumor
sample tested, up to 400-fold, compared with normal sympathetic tissue (Fig. A-5).
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This data provides evidence that the nicotinic acetylcholine receptor subunit 5 is
upregulated in both tumor initiating cells of neuroblastoma, and neuroblastoma patient
tumors. Additionally, high expression of CHRNA5 also correlates with poor patient
survival (http://home.ccr.cancer.gov/oncology/oncogenomics/). Interestingly, the 5
subunit itself is unable to form a functional nicotinic acetylcholine receptor, requiring the
presence of another alpha, and a beta subunit to be functionally active. However, in
addition to CHRNA5 overexpression, the TIC lines express, albeit at significantly lower
levels, both CHRNA7 and CHRNB2, which together, can form a rarely expressed
572 nicotinic acetylcholine receptor (Girod, Crabtree et al. 1999). Future studies will
need to confirm upregulation of the 5 subunit at the protein level. Furthermore, to
determine if CHRNA5 overexpression is physiologically relevant in neuroblastoma cells,
or can be transforming in normal cells, RNAi knockdown of the gene should be
performed, as well as overexpression of the gene in non-transformed cell lines.

References
De Bernardi, B., B. Nicolas, et al. (2003). "Disseminated neuroblastoma in children older
than one year at diagnosis: comparable results with three consecutive high-dose
protocols adopted by the Italian Co-Operative Group for Neuroblastoma." J Clin
Oncol 21(8): 1592-601.
Girod, R., G. Crabtree, et al. (1999). "Heteromeric complexes of alpha 5 and/or alpha 7
subunits. Effects of calcium and potential role in nicotine-induced presynaptic
facilitation." Ann N Y Acad Sci 868: 578-90.

169

Hansford, L. M., A. E. McKee, et al. (2007). "Neuroblastoma cells isolated from bone
marrow metastases contain a naturally enriched tumor-initiating cell." Cancer Res
67(23): 11234-43.
Smith, K. M., A. Datti, et al. (2010). "Selective targeting of neuroblastoma tumourinitiating cells by compounds identified in stem cell-based small molecule
screens." EMBO Mol Med 2(9): 371-84.

170

% of untreated sphere number

250

FS90
NB12
200

150

100

50

0
0.064

0.32

1.6

8

40

200

1000

5000

25000

MG 624, nM

Figure A-1: MG 624 kills neuroblastoma TICs, but not skin-derived neural crest
precursors
MG 624 reduces the growth rate of and/or kills neuroblastoma tumor initiating cells
(TICs, yellow bars), but promotes the growth of normal skin-derived precursors (SKPs,
blue bars) that are neural crest stem cells. The EC50 for this effect is approximately 100
nM. Data courtesy of Dr. D. Kaplan.
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Figure A-2: Nicotinic acetylcholine receptor (CHRN) subunit expression in
neuroblastoma tumor intiating cells (TICs) compared with normal sympathetic
tissue
Transcript levels of the nicotinic acetylcholine receptor subunits 3, 4, 5, 7, 2, and
4 were quantified by qPCR using FAM/BHQ labeled Taqman based probes (ABI)
relative to human 18s (house keeping gene). CHRNA5 is highly upregulated in the two
TIC lines compared with normal sympathetic tissue, while CHRNA3, CHRNA4, and
CHRNB4 expression is undetectable. CHRNA7 and CHRNB2 is lowly expressed in the
TIC lines.
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Figure A-3: CHRNA5 is upregulated in TICs compared with skin derived stem cells
and normal sympathetic tissue
Total RNA from four independently isolated tumor initiating cell lines from the bone
marrow of neuroblastoma patients (purple bars), three neural crest precursor cell lines
from human skin follicles (aqua bars), and normal sympathetic ganglia obtained from a
non-cancerous pediatric case at autopsy (yellow bar) were reverse transcribed into cDNA.
CHRNA3, CHRNA4, CHRNA5, CHRNA7, CHRNB2, and CHRNB4 transcript levels
were quantified by qPCR relative to human 18S using FAM/BHQ labeled Taqman based
probes (ABI). As in the previous TIC lines tested, CHRNA3, CHRNA4, and CHRNB4
were undetectable. CHRNA5 was upregulated 5-40 fold compared with normal
sympathetic ganglia and skin derived neural crest stem cells.
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Figure A-4: CHRNA5 is upregulated in established human neuroblastoma cell lines
compared with normal sympathetic tissue
Transcript levels of CHRNA5 and CHRNA7 in neuroblastoma cell lines were quantified
by qPCR using FAM/BHQ labeled Taqman based probes (ABI) relative to human 18s
(house keeping gene). Consistent with CHRN expression in the TIC lines, CHRNA5 is
highly upregulated in the established neuroblastoma cell lines SY5Y, KCN, and KCN-R
compared with normal sympathetic tissue. Unlike in the TICs, CHRNA7 expression in
the cell lines is equivalent to normal sympathetic tissue.
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Figure A-5: CHRNA5 is highly expressed in patient tumor samples compared with
normal sympathetic tissue
Transcript levels of CHRNA5 in neuroblastoma tumor samples were quantified by qPCR
using FAM/BHQ labeled Taqman based probes (ABI) relative to human 18s (house
keeping gene). Transcript levels of CHRNA5 in all tumor samples run together (blue
bars) and a select number of tumor samples run at the same time as cDNA from normal
sympathetic tissue (red bars). All transcript values are expressed as fold expression
relative to CHRNA5 expression in normal sympathetic tissue. Samples are ordered from
highest to lowest fold expression from left to right on the x-axis. CHRNA5 mRNA
expression is higher in all tumor samples compared with normal sympathetic tissue.
Tumor sample RNA was graciously provided by the Children’s Oncology Group (COG).
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